

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/28420 A2

(51) International Patent Classification⁷: **A61K 38/29**,
31/7088, 48/00, C12N 5/08, A61K 9/127, 7/06, 7/48,
A61P 17/00, 35/00 // (A61K 38/29, 31:59)

(74) Agents: **ESMOND, Robert, W. et al.**; Sterne, Kessler,
Goldstein & Fox P.L.L.C., 1100 New York Avenue, N.W.,
Suite 600, Washington, DC 20005-3934 (US).

(21) International Application Number: **PCT/US01/31082**

(81) Designated States (*national*): AU, CA, JP, KR, US.

(22) International Filing Date: 5 October 2001 (05.10.2001)

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/238,134 6 October 2000 (06.10.2000) US

Published:

— without international search report and to be republished
upon receipt of that report

(71) Applicant and

(72) Inventor: **HOLICK, Michael, F.** [US/US]; 31 Bishop
Lane, Sudbury, MA 01776 (US).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 02/28420 A2

(54) Title: REGULATION OF CELL PROLIFERATION AND DIFFERENTIATION USING TOPICALLY APPLIED NUCLEIC ACID MOLECULES

(57) Abstract: Methods are disclosed for the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorder, such as psoriasis, and skin cancer for enhancing wound healing, for stimulating hair growth and inhibiting hair growth, by administration of nucleic acid molecules encoding parathyroid hormone (PTH), parathyroid related peptide (PTHrP), or fragment, analog or derivative thereof, and salts thereof, encapsulated by particular liposomes or incorporated into a porous biocompatible matrix.

Regulation Of Cell Proliferation And Differentiation Using Topically Applied Nucleic Acid Molecules

Background of the Invention

Field of the Invention

5 This invention relates to the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorder, such as psoriasis, for enhancing wound healing, for stimulating hair growth, and inhibiting hair growth by topical administration of nucleic acid molecules encoding parathyroid hormone (PTH), parathyroid related peptide (PTHrP), or
10 a fragment or analog thereof.

Related Art

 U.S. Pat. Nos. 5,527,772, 5,840,690 and 6,066,618 describe methods of inhibiting proliferation and enhancing differentiation of mammalian cells, inducing proliferation of mammalian cells, enhancing wound healing, and
15 stimulating hair growth using a peptide which has a 10% or greater homology to a region of human PTH or human PTHrP. Certain fragments and analogs (e.g. PTH (1-34), PTH (3-34) and PTHrP (1-34)) were found to act as agonists of PTH and PTHrP and inhibit proliferation and enhance differentiation of mammalian cells. Other fragments and analogs (e.g. PTH (7-34) and PTHrP
20 (7-34) are antagonists of PTH and PTHrP were also found to enhance the proliferation of mammalian cells. The agonists are useful for treatment of hyperproliferative skin diseases such a psoriasis, actinic keratoses, and skin cancer and the antagonists are useful for wound healing, particularly wounds of the skin, enhancing or maintaining hair growth, particularly following
25 chemotherapeutic treatment of a mammal, and stimulating epidermal regrowth. Methods of administration include oral, nasal, intravenous, topical, subcutaneous, parenteral and intraperitoneal administration. The peptides may

- 2 -

be administered by subcutaneous pumps, patches, tapes, or by liposomal carriers.

A variety of PTH and PTHrP analogs and derivatives thereof have been made. See U.S. Pat. Nos. 4,086,196, 4,423,037, 4,771,124, 4,833,125, 4,968,669, 5,001,223, 5,087,562, 5,093,233, 5,116,952, 5,149,779, 5,171,670, 5,229,489, 5,317,010, 5,382,658, 5,393,869, 5,434,246, 5,527,772, 5,589,452, 5,807,823, 5,821,255, 5,840,690, 5,977,070, 6,025,467, 6,051,868, and 6,066,618; WO94/02510, WO00/23594, and WO00/31137; and EP 477,885. Methods for determining whether a particular analog is an agonist or antagonist of PTH and PTHrP are described in U.S. Pat. Nos. 5,527,772, 5,840,690 and 6,066,618.

Active vitamin D compounds are useful for treating hyperproliferative skin diseases and other conditions. A large number of such active vitamin D compounds are known. See U.S. Patent Nos. 5,457,217, 5,414,098, 5,384,313, 5,373,004, 5,371,249, 5,430,196, 5,260,290, 5,393,749, 5,395,830, 5,250,523, 5,247,104, 5,397,775, 5,194,431, 5,281,731, 5,254,538, 5,232,836, 5,185,150, 5,321,018, 5,086,191, 5,036,061, 5,030,772, 5,246,925, 4,973,584, 5,354,744, 4,927,815, 4,857,518, 4,851,401, 4,851,400, 4,847,012, 4,755,329, 4,940,700, 4,619,920, 4,594,192, 4,588,716, 4,564,474, 4,552,698, 4,588,528, 4,719,204, 4,719,205, 4,689,180, 4,505,906, 4,769,181, 4,502,991, 4,481,198, 4,448,726, 4,448,721, 4,428,946, 4,411,833, 4,367,177, 4,336,193, 4,360,472, 4,360,471, 4,307,231, 4,307,025, 4,358,406, 4,305,880, 4,279,826, and 4,248,791.

Summary of the Invention

The invention provides two important therapeutic methods one involving inhibition of cell proliferation and enhancement of skin cell differentiation (the agonist activity), which is useful in the treatment of psoriasis, ichthyosis, actinic keratoses, skin cancer, inhibiting hair growth or preventing hair regrowth. A second method involves enhancement of cell proliferation (the antagonist activity), which is useful in wound healing,

- 3 -

stimulating epidermal regrowth and hair growth. In addition, the invention provides methods for enhancing wound healing and hair growth based on in vivo wound healing activity or in vitro or in vivo hair growth activity rather than strict agonist or antagonist activity in vitro.

5 The first method of the invention generally involves inhibiting proliferation and enhancing differentiation of mammalian skin cells by contacting the cell with a nucleic acid molecule encoding a peptide which is preferably at least 3, and more preferably at least 8, amino acids long and has
10 10% or greater (more preferably, 50% or greater, and most preferably 75% or greater) sequence identity with a region (preferably within the amino-terminal 34 amino acid region) of human PTH or human PTHrP and, when expressed, is capable of inhibiting proliferation or enhancing the differentiation in vitro of cultured human keratinocytes; or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair growth. In preferred
15 embodiments of this method, the peptide encoded by the nucleic acid molecule is hPTH (1-84), hPTH (1-34), hPTHrP (1-31), hPTHrP (1-40), hPTH (1-44), hPTH (1-36), hPTH (1-38), hPTH (1-31), hPTH (3-34), hPTHrP (1-34), hPTHrP (1-141), hPTHrP (1-139) or hPTHrP (1-173). This method has particular application in the treatment of hyperproliferative skin disorders such
20 as psoriasis. The method may also be useful in the treatment of certain preskin cancers and skin cancers, by the inhibition of cancer cell proliferation and by the induction of differentiation and inhibition of hair growth or preventing hair growth and acne.

 The second method of the invention generally involves enhancing
25 proliferation of mammalian skin cells by contacting the skin cells with a nucleic acid molecule encoding a peptide which is preferably at least 3, and more preferably at least 8, amino acids long and has 10% or greater (more preferably, 50% or greater, and most preferably 75% or greater) sequence identity with a region (preferably within the amino-terminal 34 amino acid
30 region) of hPTH or hPTHrP and, when expressed, is capable of blocking the differentiation or the inhibition of proliferation in vitro of cultured human

- 4 -

keratinocytes by PTH (1-34) or $1,25(\text{OH})_2\text{D}_3$ or PTHrP (1-34); or *in vivo* in mouse skin by stimulating skin cell proliferation or accelerating hair cycle progression or stimulating hair growth. In a preferred embodiment of this method, the peptide encoded by the nucleic acid molecule is PTH (7-34), PTH (7-84), hPTH (5-34), hPTHrP (7-34), hPTHrP (5-34), hPTHrP (7-141), hPTHrP (7-134), or hPTHrP (7-173). In a related method of the invention, proliferation of mammalian skin cells, e.g., during wound healing, is enhanced by contacting the cell or wound with nucleic acid molecule encoding a peptide which is preferably at least 3, and more preferably at least 8, amino acids long and has 10% or greater (more preferably, 50% or greater, and most preferably, 75% or greater) sequence identity with a region (preferably, within the amino-terminal 34 amino acid region) of hPTH or hPTHrP, and, when expressed, is capable of enhancing wound healing in an *in vivo* skin punch assay. In preferred embodiments of this method, the peptide encoded by the nucleic acid molecule is hPTH (1-84), hPTH (1-34), hPTH (7-34), hPTH (5-34), hPTH (5-36), hPTH (1-31), hPTHrP (1-34), hPTHrP (1-135), hPTHrP (1-141), hPTHrP (1-173) or hPTHrP (7-34). These related methods have particular application in the enhancement of wound healing and also have applications in the promotion of skin growth in patients with burns or skin ulcerations as well as in the stimulation of epidermal regrowth in people who have decreased epidermal cell proliferation due to aging.

Hair growth is stimulated by administering to a mammal a nucleic acid molecule encoding a peptide which is preferably at least 3, and more preferably at least 8, amino acids long and has 10% or greater (more preferably, 50% or greater, and most preferably, 75% or greater) sequence identity with a region (preferably, within the amino-terminal 34 amino acid region) of hPTH or hPTHrP, and, when expressed, is capable of stimulating hair growth *in vitro* or *in vivo*. In preferred embodiments of this method, the peptide encoded by the nucleic acid molecule is hPTH (7-34), hPTH (7-84), hPTHrP (7-134), hPTHrP (7-141), hPTHrP (7-173), hPTH (5-34), hPTHrP (7-34) or hPTH (5-36).

- 5 -

The nucleic acid molecules are administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier. In a preferred embodiment, the carrier is a liposome or gel. In another preferred embodiment the nucleic acid molecules are contained within a porous biocompatible matrix.

The invention also relates to a method of inhibiting proliferation or enhancing differentiation of a skin or hair cell of a mammal, comprising administering to the mammal in need thereof a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule of the invention and an active vitamin D compound, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth. The invention also relates to a composition comprising a nucleic acid molecule of the invention encapsulated within a liposome.

The invention also relates to a composition comprising a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule of the invention and an active vitamin D compound, optionally encapsulated within a liposome.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Brief Description of the Figures

FIG. 1 depicts a bar graph showing the effect of transfecting PTHrP (1-141) and PTHrP (1-173) genes into cultured keratinocytes on ³H-thymidine incorporation. Bar 1 represents the empty vector, Bar 2 represents the PTHrP

- 6 -

gene (1-141) transfected into cultured human keratinocytes, Bar 3 represents the PTHrP gene (1-173) transfected into cultured human keratinocytes.

FIGs. 2A-2C depict schematic representations of the cDNA structure of the PTHrP (1-139), PTHrP (1-141) and PTHrP (1-173) genes.

5 FIG. 3 depicts a schematic representation of the pACCMV.pLpa adenoviral expression vector.

FIG. 4 depicts the sequence of SEQ ID NO: 1.

FIG. 5 depicts the sequence of SEQ ID NO: 2.

FIG. 6 depicts the sequence of SEQ ID NO: 3.

10 FIG. 7 depicts the sequence of SEQ ID NO: 4.

FIG. 8 depicts the sequence of SEQ ID NO: 5.

FIG. 9 depicts the sequence of SEQ ID NO: 6.

FIG. 10 depicts the sequence of SEQ ID NO: 7.

FIG. 11 depicts the sequence of SEQ ID NO: 8.

15 FIG. 12 depicts the sequence of SEQ ID NO: 9.

FIG. 13 depicts the sequence of SEQ ID NO: 10.

FIG. 14 depicts the sequence of SEQ ID NO: 11.

FIG. 15 depicts the sequence of SEQ ID NO: 12.

FIG. 16 depicts the sequence of SEQ ID NO: 13.

20 FIG. 17 depicts the sequence of SEQ ID NO: 14.

FIG. 18 depicts the sequence of SEQ ID NO: 15.

FIG. 19 depicts the sequence of SEQ ID NO: 16.

FIG. 20 depicts the sequence of SEQ ID NO: 17.

FIG. 21 depicts the sequence of SEQ ID NO: 18.

25 FIG. 22 depicts the sequence of SEQ ID NO: 19.

FIG. 23 depicts the sequence of SEQ ID NO: 20.

FIG. 24 depicts the sequence of SEQ ID NO: 21.

FIG. 25 depicts the sequence of SEQ ID NO: 22.

FIG. 26 depicts the sequence of SEQ ID NO: 23.

30 FIG. 27 depicts the sequence of SEQ ID NO: 24.

FIG. 28 depicts the sequence of SEQ ID NO: 25.

- 7 -

FIG. 29 depicts the sequence of SEQ ID NO: 26.

FIG. 30 depicts the sequence of SEQ ID NO: 27.

FIG. 31 depicts the sequence of SEQ ID NO: 28.

FIG. 32 depicts the sequence of SEQ ID NO: 29.

5 FIG. 33 depicts the sequence of SEQ ID NO: 30.

FIG. 34 depicts the sequence of SEQ ID NO: 31.

FIG. 35 depicts the sequence of SEQ ID NO: 32.

FIG. 36 depicts the sequence of SEQ ID NO: 33.

FIG. 37 depicts the sequence of SEQ ID NO: 34.

10 FIG. 38 depicts the sequence of SEQ ID NO: 35.

FIG. 39 depicts the sequence of SEQ ID NO: 36.

FIG. 40 depicts the sequence of SEQ ID NO: 37.

FIG. 41 depicts the sequence of SEQ ID NO: 38.

FIG. 42 depicts the sequence of SEQ ID NO: 39.

15 FIG. 43 depicts the sequence of SEQ ID NO: 40.

FIG. 44 depicts the sequence of SEQ ID NO: 41.

FIG. 45 depicts the sequence of SEQ ID NO: 42.

FIG. 46 depicts the sequence of SEQ ID NO: 43.

FIG. 47 depicts the sequence of SEQ ID NO: 44.

20

Description of the Preferred Embodiments

Nucleic Acid Molecules of the Invention

The invention relates to the regulation of cell differentiation and proliferation by administration of nucleic acid molecules encoding parathyroid hormone (PTH), parathyroid hormone related protein (PTHrP), or a fragment
25 or analog thereof. Particular nucleic acid molecules which can be used include those which encode the following peptides:

- 8 -

hPTH (1-84), encoded by nucleotides 1-252 of the nucleic acid molecule of SEQ ID NO: 1 (Kimura, T. *et al.*, *BBRC* 11:493 (1983); Fairwell, T. *et al.*, *Biochemistry* 22:691 (1983)).

hPTH (1-31), encoded by nucleotides 1-93 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (1-34), encoded by nucleotides 1-102 of the nucleic acid molecule of SEQ ID NO: 1.

HPTH (1-36), encoded by nucleotides 1-108 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (1-38), encoded by nucleotides 1-114 of the nucleic acid molecule of SEQ ID NO:1 (Heech, R. D. *et al.*, *Horm. Metab. Res.* 16:556 (1984)).

hPTH (1-44), encoded by nucleotides 1-132 of the nucleic acid molecule of SEQ ID NO:1 (Kimura T. *et al.*, *Biopolymers* 20:1823 (1981)).

hPTH (5-36), encoded by nucleotides 13-108 of the nucleic acid molecule of SEQ ID NO:1.

HPTH (7-34), encoded by nucleotides 19-102 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (13-34), encoded by nucleotides 40-102 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (28-48), encoded by nucleotides 82-144 of the nucleic acid molecule of SEQ ID NO: 1 (Rosenblatt, M. *et al.*, *Biochemistry* 16:2811 (1977)).

HPTH (7-84), encoded by nucleotides 19-252 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (53-84), encoded by nucleotides 157-252 of the nucleic acid molecule of SEQ ID NO:1 (Rosenblatt, M. *et al.*, *Endocrinology* 103:976 (1978)).

hPTH (64-84), encoded by nucleotides 190-252 of the nucleic acid molecule of SEQ ID NO:1.

hPTH (70-84), encoded by nucleotides 208-252 of the nucleic acid molecule of SEQ ID NO:1.

- 9 -

[Tyr¹]-hPTH (1-34), encoded by nucleotides 1-102 of the nucleic acid molecule of SEQ ID NO: 1, wherein the adenosine at position 2 is mutated to a cytosine.

5 [Tyr²⁷]-hPTH (27-48), encoded by nucleotides 79-144 of the nucleic acid molecule of SEQ ID NO: 1, wherein the adenosine at position 79 and the guanosine at position 81 are both mutated to a thymidine.

[Tyr⁶³]-hPTH (63-84), encoded by nucleotides 187-252 of the nucleic acid molecule of SEQ ID NO: 1, wherein the cytosine at position 187 is mutated to a thymidine.

10 [Tyr⁶⁹]-hPTH (69-84), encoded by nucleotides 205-255 of the nucleic acid molecule of SEQ ID NO: 1, wherein the guanosine at position 205 is mutated to a thymidine, and the guanosine at position 207 is mutated to either a thymidine or a cytosine.

15 PTH, Bovine (bPTH) (1-84), encoded by nucleotides 1-252 of the nucleic acid molecule of SEQ ID NO: 2.

bPTH (1-34), encoded by nucleotides 1-102 of the nucleic acid molecule of SEQ ID NO: 2 (Tregear, G. W. *et al.*, *Biochemistry* 16:2817 (1977)).

bPTH (3-34), encoded by nucleotides 7-102 of the nucleic acid molecule of SEQ ID NO: 2 (Lowrik, C. *et al.*, *Cell Calcium* 6:311 (1985)).

20 PTHrP (1-31), encoded by nucleotides 1-93 of the nucleic acid molecule of SEQ ID NO: 3.

PTHrP (1-40), encoded by nucleotides 1-120 of the nucleic acid molecule of SEQ ID NO: 3.

25 PTHrP (5-36), encoded by nucleotides 13-108 of the nucleic acid molecule of SEQ ID NO: 3.

PTHrP (7-34), encoded by nucleotides 19-102 of the nucleic acid molecule of SEQ ID NO: 3.

PTHrP (7-139), encoded by nucleotides 19-417 of the nucleic acid molecule of SEQ ID NO: 3.

30 PTHrP (7-141), encoded by nucleotides 19-423 of the nucleic acid molecule of SEQ ID NO: 3.

- 10 -

PTHrP (7-173), encoded by nucleotides 19-519 of the nucleic acid molecule of SEQ ID NO: 3.

Rat PTH (rPTH) (1-84), encoded by nucleotides 1-252 of the nucleic acid molecule of SEQ ID NO: 4 (Heinrich, G. *et al.*, *J. Biol. Chem.* 25:3320 (1984)).

In addition, nucleic acid molecules which encode the peptides and peptide derivatives disclosed in the following documents can also be used: U.S. Pat. Nos. 4,086,196, 4,423,037, 4,771,124, 4,833,125, 4,968,669, 5,001,223, 5,087,562, 5,093,233, 5,116,952, 5,149,779, 5,171,670, 5,229,489, 5,317,010, 5,382,658, 5,393,869, 5,434,246, 5,527,772, 5,589,452, 5,807,823, 5,821,255, 5,840,690, 5,977,070, 6,025,467, 6,051,868, and 6,066,618; WO94/02510, WO00/23594, and WO00/31137; and EP 477,885.

A typical design for constructing the PTH (7-34), (7-84), (7-141), and PTHrP (7-34), (7-139), and (7-173) fragment cDNAs is to place a ATG start codon upstream of the initial peptide codon of the individual fragments and to introduce a stop codon downstream of the final peptide codon of the individual fragments. Also, an endogenous peptide cleavage site will be introduced between the ATG start codon and the initial peptide codon of the individual fragments to avoid unwanted amino acids being introduced into the constructs.

When selecting a candidate nucleic acid molecule for a method of this invention, a preferred first step is to choose a nucleic acid molecule encoding a peptide which includes a fragment which has at least 10%, and more preferably 50% or greater, sequence identity with an 8 or greater amino acid long fragment within the amino terminal 34 amino acid region of hPTH or hPTHrP. The term "sequence identity" refers to a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. (See, *e.g.*: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer*

- 11 -

Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

5 While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in
10 Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG
15 program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(i):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., *et al.*, *J. Molec Biol* 215:403 (1990)).

Therefore, as used herein, the term "identity" represents a comparison between a test and reference sequence. More specifically, reference test
20 sequence is defined as any test sequence that is 10% or more identical to a reference sequence. As used herein, the term at least 10% identical to refers to percent identities from 10 to 99.99 relative to the reference sequence. Identity at a level of 10% or more is indicative of the fact that, assuming for exemplification purposes a test and reference sequence length of 100 amino
25 acids, that no more than 90% (i.e., 90 out of 100) of the amino acids in the test sequence differ from that of the reference sequence. Such differences may be represented as point mutations randomly distributed over the entire length of the nucleotide or amino acid sequence of the invention or they may be clustered in one or more locations of varying length up to the maximum
30 allowable amino acid difference. Differences are defined as nucleotide or amino acid substitutions, or deletions.

- 12 -

Because of the high degree of homology among human PTH and PTH of other species, PTH peptides encoded by nucleic acids from non-human as well as human sources can be used. Similarly, human PTHrP (1-139), (1-141) and (1-173) have a high degree of homology with PTHrP of other species; therefore, nucleic acids from non-human as well as human sources can be used in the methods of the invention involving PTHrP.

Candidate nucleic acid molecules may be tested for suitability as inhibitors of cell proliferation and enhancers of differentiation using cultured human keratinocytes, similar to the method for testing peptides described in U.S. Pat. Nos. 5,527,772, 5,840,690 and 6,066,618. Briefly, those nucleic acid molecules encoding peptides which inhibit proliferation and induce differentiation in cultured keratinocytes are those potentially useful as therapeutic agents in treating disorders, e.g., psoriasis and cancer, where suppression of cell proliferation is desired. Candidate nucleic acid molecules may be tested for suitability as enhancers of cell proliferation using cultured human keratinocytes or *in vivo* mouse model. Those peptides encoded by the nucleic acid molecules which block the effect of agonist peptides or $1,25(\text{OH})_2\text{D}_3$ on cultured keratinocyte proliferation are those potentially useful as therapeutic agents in treating disorders, e.g., wounds, burns, or skin ulcerations, where maintenance or stimulating of cell proliferation is desired.

Candidate nucleic acid molecules may be tested for their ability to enhance wound healing by carrying out a skin punch biopsy test, as described in U.S. Pat. Nos. 5,527,772, 5,840,690 and 6,066,618.

Candidate peptides may be tested for suitability as stimulators of hair growth using an *in vitro* hair growth assay, as described in U.S. Pat. Nos. 5,527,772, 5,840,690 and 6,066,618. Those peptides encoded by the nucleic acid molecules which stimulate hair growth *in vitro* are those potentially useful for the stimulation of hair growth *in vivo*, e.g., for the stimulation or maintenance of hair growth during or following chemotherapy or to treat a form of alopecia, e.g., male and female pattern baldness.

Alternatively, *in vivo* assays may be carried out as described herein and similar to those described in Schilli, M.B. *et al.*, *J. Invest. Dermatol.* 108:928-932 (1997); Holick, M.F., *et al.*, *Proc. Natl. Acad. Sci.* 91:8014-8016 (1994); Paus, R. and Cotsarelis, G., *N. Engl. J. Med.* 341: 491-497 (1999); Paus, R., *et al. Laboratory Invest.* 60: 365-369 (1989) and U.S. Pat. App. No. 60/213,247.

Care should be taken when determining the correct nucleic acid molecule for use in the invention. Experiments have shown that when normal cultured human keratinocytes are transfected with plasmids containing PTHrP (1-141) or PTHrP (1-173) an unexpected enhancement of cell growth is seen, as measured by ³H-thymidine incorporation into epidermal DNA (FIG. 1). These results are attributed to proteolysis of the full-length peptide. For this reason, all candidate nucleic acid molecules should be tested for the expected activity before use.

Gene Therapy

In this preferred embodiment of the invention, a nucleic acid molecule encoding a peptide with desired activity is incorporated into a polynucleotide construct suitable for introducing the nucleic acid molecule into cells of the animal to be treated, to form a transfection vector. The transfection vector is then introduced into selected target tissues of the cells of the animal *in vivo* using any of a variety of methods known to those skilled in the art. Alternatively, naked DNA may be transfected into the cells, with or without cationic lipids.

Techniques for the construction of transfection vectors containing inserts of desired nucleic acid sequences are well-known in the art, and are generally described in "Working Toward Human Gene Therapy," Chapter 28 in *Recombinant DNA, 2nd Ed.*, Watson, J.D. *et al.* (eds.), Scientific American Books: New York (1992), pp. 567-581, or Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York (1989).

- 14 -

Gene therapy approaches that may be used to deliver a nucleic acid molecule include injection of plasmid DNA (Horton, H.M., *et al.*, *Proc. Natl. Acad. Sci. USA* 96(4):1553-1558 (1999)); transduction using adenoviral vectors (Waugh, J.M., *et al.*, *Proc. Natl. Acad. Sci. USA* 96(3):1065-1070 (1999)); transduction using retroviral vectors (Axelrod, J.H., *et al.*, *Proc. Natl. Acad. Sci. USA* 87:5173-5177 (1990); Drumm, M.L., *et al.*, *Cell* 62:1227-1233 (1990); Krueger, G.G., *et al.*, *J. Invest. Dermatol.* 112:233-239 (1999); Palmer, T.D., *et al.*, *Blood* 73:438-445 (1989); and Rosenberg, S.A., *et al.*, *N. Eng. J. Med.* 323:570-578 (1990)); and gene transfer using liposomes (Mason, C.A.E., *et al.*, *Nature Medicine* 5(2):176-182 (1999)). In addition, general methods for construction of gene therapy vectors and the introduction of such vectors into a mammal for therapeutic purposes may be obtained in the above-referenced publications, the disclosures of which are specifically incorporated herein by reference in their entirety. In one such general method, vectors containing nucleic acid sequences of the present invention are directly introduced into the cells or tissues of the mammal to be treated, preferably by topical application. Such an approach is generally referred to as "*in vivo*" gene therapy.

Alternatively, cells or tissues may be removed from the mammal to be treated and placed into culture according to methods that are well-known to one of ordinary skill in the art. Transfection vectors or naked DNA containing the genes for desired peptides may then be introduced into these cells or tissues by any of the methods described generally above for introducing isolated polynucleotides into a cell or tissue. After a sufficient amount of time to allow incorporation of the inserted DNA, the cells or tissues may then be re-inserted into the mammal to be treated. Since introduction of the nucleic acid molecule encoding the peptide is performed outside of the body of the mammal, this approach is generally referred to as "*ex vivo*" gene therapy. See U.S. Patent No. 5,399,346. Gene transfer through transfection of cells *ex vivo* can be performed by a variety of methods, including, for example, calcium phosphate precipitation,

- 15 -

diethylaminoethyl dextran, electroporation, lipofection, or viral infection. Such methods are well known in the art (see, for example, Sambrook *et al.*).

For both *in vivo* and *ex vivo* gene therapy, the nucleic acid molecule encoding the desired peptide of the invention may be operatively linked to a regulatory DNA sequence, or "promoter," to form a genetic construct as described above. This construct, containing both the promoter and the nucleic acid molecule encoding the peptide, may be subcloned into a suitable vector such as a plasmid, adenovirus vector, retrovirus vector, or the like, and introduced into the animal to be treated in an *in vivo* gene therapy approach, or into the cells or tissues of the mammal in an *ex vivo* approach.

Alternatively, the nucleic acid molecule of the invention may be operatively linked to a heterologous regulatory DNA sequence, or promoter, to form a genetic construct as described above. The heterologous regulatory sequence may be tissue specific. The vector containing the genetic construct is then directly introduced into the animal to be treated or into the cells or tissues of the animal, as described.

The term "operably linked", as used herein, denotes a relationship between a regulatory region (typically a promoter element, but may include an enhancer element) and the gene, whereby the transcription of the gene is under the control of the regulatory region.

The term "heterologous" means a DNA sequence not found in the native genome. That is, two nucleic acid elements are said to be "heterologous" if the elements are derived from two different genes, or alternatively, two different species. Thus, "heterologous DNA regulatory sequence" indicates that the regulatory sequence is not naturally ligated to the nucleic acid molecule selected for use in the invention.

The term "promoter" is used according to its art-recognized meaning. It is intended to mean the DNA region, usually upstream to the coding sequence of a gene, which binds RNA polymerase and directs the enzyme to the correct transcriptional start site.

- 16 -

In general, a promoter may be functional in a variety of tissue types and in several different species of organisms, or its function may be restricted to a particular species and/or a particular tissue. Further, a promoter may be constitutively active, or it may be selectively activated by certain substances (e.g., a tissue-specific factor), under certain conditions (e.g., in the presence of an enhancer element, if present, in the genetic construct containing the promoter), or during certain developmental stages of the organism (e.g., active in fetus, silent in adult).

Promoters useful in the practice of the present invention are preferably "tissue-specific"--that is, they are capable of driving transcription of a gene in one tissue while remaining largely "silent" in other tissue types. Examples of tissue-specific promoters in the skin are the Keratin promoter (Vassar *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 86:8565 (1989)), the POMC promoter (Deen *et al.* *Mol. Biol. Evol.* 9:483 (1992)), the alpha-actin promoter (Shani, *Mol. Cell Biol.*, 6:2624 (1986)), the elastase-q promoter (Swift *et al.*, *Cell* 28:639 (1984)), the tyrosine hydroxylase promoter (Kim, L. S., *et al.*, *J. Biol. Chem* 268:15689 (1993); Kaneda, N., *et al.*, *Neuron* 6:583 (1991)), the dopamine beta-hydroxylase promoter (Mercer E. H., *et al.*, *Neuron* 7:703 (1991); Hcyle, G. W., *et al.*, *J. Neurosci.* 14:2455 (1994)), the tryptophan hydroxylase promoter (Boularand, S., *et al.*, *J. Biol. Chem* 270:3757 (1995); Stoll, J. and Goldman, D., *J. Neurosci. Res.* 28:457 (1991)) and the parathyroid hormone-related peptide promoter (Campos, R. V., *et al.*, *Mol. Rnfovtinol.* 6:1642). For additional examples of tissue-specific promoters, see U.S. Patent Nos. 5,834,306 and 5,416,027, and references cited therein.

In addition to a promoter, the genetic construct may also contain other genetic control elements, such as enhancers, repressible sequences, and silencers, which may be used to regulate replication of the vector in the target cell. The only requirement is that the genetic element be activated, derepressed, enhanced, or otherwise genetically regulated by factors in the host cell and, with respect to methods of treatment, not in the non-target cell.

- 17 -

An "element," when used in the context of nucleic acid constructs, refers to a region of the construct or a nucleic acid fragment having a defined function.

For example, an enhancer element, as used herein, is a region of DNA that, when associated with inserted nucleic acid molecule, operably linked to a promoter, enhances the transcription of that gene.

The term "enhancer" is used according to its art-recognized meaning. It is intended to mean a sequence found in eukaryotes which can increase transcription from a gene when located (in either orientation) up to several kilobases from the gene being studied. These sequences usually act as enhancers when on the 5' side (upstream) of the gene in question. However, some enhancers are active when placed on the 3' side (downstream) of the gene. In some cases, enhancer elements can activate transcription from a gene with no (known) promoter.

Preferred enhancers include the DF3 breast cancer-specific enhancer and enhancers from viruses and the steroid receptor family. Other preferred transcriptional regulatory sequences include NF1, SP1, AP1, and FOS/JUN.

Any of a variety of methods known to those skilled in the art may be used to introduce transfection vectors of the present invention into selected target tissue cells. Such methods include, for example, viral-mediated gene transfer using retroviruses, adeno-associated virus (AAV), herpes virus, vaccinia virus, or RNA viruses (e.g., Grunhaus and Horowitz, *Semin. Virol.* 3:237-252 (1992); Herz and Gerard, *Proc. Nat. Acad. Sci. USA* 90:2812-2816 (1993); and Rosenfeld *et al.*, *Cell* 68:143-155 (1992)); liposome-mediated gene transfer (Morishita *et al.*, *J. Clin. Invest.* 91:2580 (1993); Felgner *et al.*, U.S. Patent Nos. 5,703,055 (1997) and 5,858,784 (1999)); injection of naked DNA directly into a target tissue (e.g., Felgner *et al.*, U.S. Patent No. 5,589,466 (1996); Wolff *et al.*, U.S. Patent No. 5,693,622 (1997)); and receptor-mediated gene transfer (Wu and Wu, *Biochemistry* 27:887-892 (1988); Wagner *et al.*, *PNAS USA* 87:3410-3414 (1990); Curiel *et al.*, U.S. Patent 5,547,932 (1996); and Beug *et al.*, U.S. Patent No. 5,354,844 (1994)).

In any of these methods, where a vector may be targeted to selectively transfect a specific population of cells, it will be understood that in addition to local administration (such as may be achieved by injection into the target tissue), the vector may be administered systemically (e.g., intravenously) in a biologically-compatible solution or pharmaceutically acceptable delivery vehicle. Vector constructs administered in this way may selectively infect the target tissue. According to the present invention, the presence of a target tissue-specific promoter on the construct provides an independent means of restricting expression of the therapeutic gene.

Nucleic acid molecules encoding peptides which block antiproliferative compounds can also be useful in conjunction with chemotherapeutic agents in the treatment of skin cancer; many chemotherapeutic agents are effective only against dividing cells, and the blocking peptides can have the effect of inducing division of otherwise dormant cells, rendering them vulnerable to the chemotherapy. Nucleic acids encoding blocking peptides can also be useful in promoting growth of new cells, e.g., skin cells, in topical skin creams. Differentiation-inducing peptides can be used as immunostimulants, by inducing maturation of monocytes and lymphocytes bearing PTH receptors, while blocking peptides can be used to inhibit lymphocyte maturation, and thus can be used to treat conditions, e.g., autoimmune diseases such as juvenile diabetes, rheumatoid arthritis, and allograft rejection, where mature lymphocytes are a causative agent.

The nucleic acid molecules of the invention can be admixed with a pharmacologically inert topical carrier such as one comprising a gel, an ointment or a cream, including such carriers as water, glycerol, alcohol, propylene glycol, fatty alcohol, triglycerides, fatty acid ester or mineral oils. Other possible carriers are liquid petrolatum, isopropylpalmitate, polyethylene glycol ethanol 95%, polyoxyethylene monolaurate 5% in water, sodium lauryl sulfate 5% in water, and the like. Materials such as antioxidants, humectants, viscosity stabilizers and the like may be added, if necessary. Nucleic acid molecules can be incorporated into liposomes using methods outlined in U.S. Pat. 5,260,065.

- 19 -

The nucleic acid molecules can be incorporated into a collagenous biocompatible matrix similar to the methods utilized in Fang *et al.*, *Proc. Nat. Acad. Sci. U.S.A.* 93:5753 (1996) and U.S. Pat. 5,962,427. The types of matrices that may be used in the practice of the invention is virtually limitless and may include both biological and synthetic matrices. The matrices may be biodegradable or non-biodegradable. The matrices may take the form of sponges, implants, tubes, telfa pads, band-aids, bandages, pads, lyophilized components, gels, patches, powders or nanoparicles. Particular examples of such matrices include porous or collagenous materials (e.g. type II collagen), hydroxyapatite, bioglass, aluminates, bioceramic materials, purified proteins or extracellular matrix compositions as well as metals such as titanium.

The nucleic acid molecules can be provided in the form of pharmaceutically acceptable salts. Examples of preferred salts are those of therapeutically acceptable organic acids, e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, salicylic, methanesulfonic, toluenesulfonic, or pamoic acid, as well as polymeric acids such as tannic acid or carboxymethyl cellulose, and salts with inorganic acids such as hydrohalic acids, e.g., hydrochloric acid, sulfuric acid, or phosphoric acid.

Dosage will be dependent upon the age, health, and weight of the recipient; kind of concurrent treatment, if any; frequency of treatment; and the nature of the effect desired. Generally, daily dosage may be 0.001 to 500 µg/kg. The topical dosage may be from 0.01 to 100 µg/cm². The liposomal gel, ointment or cream formulations may be applied by one or more applications per day.

The invention also relates to compositions comprising a nucleic acid molecule of the invention, an active vitamin D compound and a pharmaceutical carrier, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when

- 20 -

expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair growth. A large number of active vitamin D compounds are known which can be used in the practice of the present invention. See U.S. Patent Nos. 5,457,217, 5,414,098, 5,384,313, 5,373,004, 5,371,249, 5,430,196, 5,260,290, 5,393,749, 5,395,830, 5,250,523, 5,247,104, 5,397,775, 5,194,431, 5,281,731, 5,254,538, 5,232,836, 5,185,150, 5,321,018, 5,086,191, 5,036,061, 5,030,772, 5,246,925, 4,973,584, 5,354,744, 4,927,815, 4,857,518, 4,851,401, 4,851,400, 4,847,012, 4,755,329, 4,940,700, 4,619,920, 4,594,192, 4,588,716, 4,564,474, 4,552,698, 4,588,528, 4,719,204, 4,719,205, 4,689,180, 4,505,906, 4,769,181, 4,502,991, 4,481,198, 4,448,726, 4,448,721, 4,428,946, 4,411,833, 4,367,177, 4,336,193, 4,360,472, 4,360,471, 4,307,231, 4,307,025, 4,358,406, 4,305,880, 4,279,826, and 4,248,791. A preferred active vitamin D compound is calcipotriene. In this embodiment, any conventional liposome may be used including the liposomes described in U.S. Pat. Nos. 4,235,871, 4,241,046, 4,247,411, 4,356,167, 4,377,567, 4,544,545, 4,551,288, 4,610,868, 4,731,210, 4,744,989, 4,772,471, 4,897,308, 4,917,951, 5,021,200, 5,032,457, and 5,260,065.

The invention relates as well to a method of inhibiting proliferation or enhancing differentiation of a skin or hair cell of a mammal, comprising administering to the mammal in need thereof a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule of the invention and an active vitamin D compound, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth. In this embodiment, the nucleic acid molecule encoding the peptide

- 21 -

and the active vitamin D compound may be administered as part of single or separate pharmaceutical compositions. Either one or both of the nucleic acid molecules and active vitamin D compound may be administered topically or parenterally. In a preferred embodiment, the nucleic acid molecule is administered first followed by the active vitamin D compound.

The following examples are illustrative, but not limiting, of the method and compositions of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.

Example 1

Mini-gene construction

PTHrP gene: PTHrP gene expresses three isoform peptides: PTHrP 1-139, PTHrP1-141 and PTHrP 1-173. The gene splicing happens between exon 4 to exon 6. The 5'-flanking regions share common nucleotide sequences, including precursor peptide. PTHrP mini-genes were made based on the nucleotide sequences of the human PTHrP/PLP gene, (Yasuda *et al. J. Biol. Chem.* 264:7720 (1989)) by using the PCR technique. The interested gene fragments were constructed into pCR3.1eukaryotic expression vector. The forward primer for PTHrP (1-139), PTHrP (1-141), PTHrP (1-173) and PTHrP (1-34) is 5'-AGCGGAGACGATGCAGCGGAGA-3' (SEQ ID NO: 26), reverse primer for PTHrP (1-139) is 5'-AAGGGAGGCAGCTGAGACG-3' (SEQ ID NO: 27), for PTHrP (1-141) is 5'-GTCCTTGGAAGGTCTCTGCTG-3' (SEQ ID NO: 28), for PTHrP (1-173) is 5'-TTCTAGTGCCACTGCCCATTTG-3' (SEQ ID NO:29) and for PTHrP (1-34) is 5'-CTACTAAGCTGTGTGGATTTCTGCGAT-3' (SEQ ID NO:

- 22 -

30). PCR was performed at 94°C for 3 min initial denaturing, then followed by denaturing for 30 seconds at 94°C, annealing for 30 seconds at 60°C and extension for 1 min at 72°C, total 30 cycles, additional extension for 10 min at 72°C.

5

Adenovirus construction of PTHrP

The corresponding mature and fragment forms of PTH or PTHrP cDNAs (FIG. 2) can be subcloned into the adenovirus expression vector, pACCMV.pLpA (FIG. 3). Once the PTH and PTHrP inserts are subcloned and purified they are co-transfected with pJM17 in 293 cells, which contains essential elements of the adenovirus genome to replicate and produce recombinant virions. The virions isolated for the co-transfected 293 cells are infectious but don't have the capacity to replicated in other cell types except 293 cells with the pJM17 vector. The purified pACCMV.pLpA. PTHrP virion particles can then be used for gene transfer of the various PTHrPs cDNAs driven by the CMV promoter in culture and animals (Tomas C. Berker, *et al.* Methods of Cell Biology, Use of Recombinant Adenovirus for Metabolic Engineering of Mammalian Cells, Vol. 43, Chp 8; pg. 161-187, Academic Press Inc., San Diego, CA., USA. 1994).

15
20

Transfection

Keratinocytes were maintained in MCDB-153 medium. Cells in 24 well dishes at 50%-60% confluence were transfected with 1 µg/ml of PTHrP cDNA which was constructed into pCR3.1 vector (INVITROGEN, San Diego, CA., USA), empty vector as a control. For each transfection, 0.5 micrograms of DNA and 3 microliters of LIPOFECTAMINE were diluted in 50 microliters of serum free media, respectively, and then combined for a DNA/ Liposome

25

complexing incubation for 15 minute at room temperature. DNA/ Liposome complex was then incubated on the cells for 3 hours. After 3 hour of transfection, fresh media was added and cells were incubated for 21 hours.

5 ***³H - Thymidine Incorporation***

³H-thymidine incorporation into DNA was used as an index of cell proliferation as described previously (Smith E.L. *et al. J. Invert. Dermatology* 86:709 (1986), Holick *et al. Proc. Nat. Acad. Sci. U.S.A.* 91:8014 (1994)). Twenty-four hours post transfection the medium was replaced with 0.5 ml of
10 fresh basal medium containing [methyl-³H]thymidine (New England Nuclear, Boston, MA) and incubated for 3 h at 37° C. ³H-Thymidine incorporation into DNA was stopped by placing the 24-well plates on ice. Unincorporated ³H-thymidine was then removed and the cells were washed three times with ice-cold phosphate-buffered saline. DNA labeled with ³H-thymidine and other
15 macromolecules were first precipitated with ice-cold 5% perchloric acid for 20 min and then extracted with 0.5 ml of 5% perchloric acid at 70 °C for 20 min. The radioactivity in the extracts was determined by a liquid scintillation counter. The results were expressed as percent of control.

Experiments have shown that when normal cultured human
20 keratinocytes are transfected with plasmids containing PTHrP (1-141) or PTHrP (1-173) an unexpected enhancement of cell growth is seen, as measured by ³H-thymidine incorporation into epidermal DNA (FIG. 1). These results may be due to proteolysis of the full length peptide.

Having now fully described this invention, it will be understood by
25 those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated by

- 24 -

reference herein in their entirety.

What Is Claimed Is:

1. A method of inhibiting proliferation or enhancing differentiation of a mammalian skin or hair cell, said method comprising administering to the mammalian skin or hair cell in need of inhibited proliferation or enhanced differentiation with a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth.

2. The method of claim 1, wherein said nucleic acid molecule is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

3. The method of claim 2, wherein said carrier is a liposome.

4. The method of claim 1, wherein said nucleic acid molecule is contained within a porous biocompatible matrix.

5. The method of claim 1, wherein said peptide encoded by the nucleic acid molecule is PTH (1-34) (SEQ ID NO: 18), PTHrP (1-34) (SEQ ID NO: 31), PTH (1-84) (SEQ ID NO: 15), PTHrP (1-141) (SEQ ID NO: 32), PTHrP (1-139) (SEQ ID NO: 33) or PTHrP (1-173) (SEQ ID NO: 34).

- 26 -

6. The method of claim 1, wherein said nucleic acid molecule is one of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, or a fragment thereof.

7. The method of claim 1, wherein said nucleic acid molecule is administered topically to the mammalian skin or hair cells.

8. The method of claim 1, wherein said method is a method of inhibiting a hyperproliferative skin disorder.

9. The method of claim 8, wherein said hyperproliferative skin disorder is psoriasis, ichthyosis, eczema, acne, actinic keratosis, or skin cancer.

10. The method of claim 1, wherein said method is a method of inhibiting hair growth or preventing hair regrowth.

11. The method of claim 1, wherein said peptide encoded by the nucleic acid molecule has at least 75% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP.

12. The method of claim 1, further comprising administering to the mammalian hair or skin cell an effective amount of an active vitamin D compound.

13. The method of claim 12, wherein said active vitamin D compound is calcipotriene.

14. The method of claim 12, wherein said active vitamin D compound is 1,25-dihydroxyvitamin D₃.

- 27 -

15. The method of claim 12, wherein said active vitamin D compound is 19-nor-1,25-dihydroxyvitamin D₂.

16. The method of claim 12, wherein said active vitamin D compound is 19-nor-1,25-dihydroxyvitamin D₃.

5 17. The method of claim 12, wherein said nucleic acid molecule and active vitamin D compound are administered topically or parenterally.

18. The method of claim 1, wherein said nucleic acid molecule is operably linked to a promoter.

10 19. The method of claim 1, wherein said nucleic acid molecule is contained by a plasmid.

20. The method of claim 1, wherein said nucleic acid molecule is contained by a viral vector.

15 21. A method of inhibiting proliferation or enhancing differentiation of a skin or hair cell of a mammal, said method comprising administering to the mammal in need thereof a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule and an active vitamin D compound, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when
20 expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth.

- 28 -

22. The method of claim 21, wherein said nucleic acid molecule and said active vitamin D compound are administered as part of a single pharmaceutical composition.

23. The method of claim 21, wherein said nucleic acid molecule and said active vitamin D compound are administered as part of separate pharmaceutical compositions.

24. The method of claim 21, wherein said nucleic acid molecule is administered parentally.

25. The method of claim 21, wherein said active vitamin D compound is administered topically.

26. The method of claim 21, wherein said active vitamin D compound is administered orally.

27. The method of claim 21, wherein said nucleic acid molecule is encapsulated within a liposome.

28. The method of claim 21, wherein said nucleic acid molecule is contained within a porous biocompatible matrix.

29. A method of inducing proliferation of a mammalian skin or hair cell, said method comprising administering to the mammalian skin or hair cell in need of proliferation with a proliferation-inducing amount of a nucleic acid molecule, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro

- 29 -

of cultured human keratinocytes by PTH (1-34), $1,25(\text{OH})_2\text{D}_3$ or PTHrP (1-34), or *in vivo* in mouse skin by stimulating skin cell proliferation or accelerating hair cycle progression or stimulating hair cell growth.

5 30. The method of claim 29, wherein said nucleic acid molecule is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

 31. The method of claim 30, wherein said carrier is a liposome.

 32. The method of claim 29, wherein said nucleic acid molecule is contained within a porous biocompatible matrix.

10 33. The method of claim 29, which is a method of stimulating skin cell growth, rejuvenating aged skin, preventing skin wrinkles, treating skin wrinkles, enhancing wound healing, stimulating hair growth, maintaining hair growth, treating or preventing female or male pattern baldness, or treating chemotherapy induced alopecia.

15 34. The method of claim 29, which is a method of stimulating epidermal cell growth or hair follicle cell growth.

 35. The method of claim 29, wherein said peptide encoded by the nucleic acid molecule is PTH (7-34) (SEQ ID NO: 35), PTHrP (7-34) (SEQ ID NO: 36), PTH (5-36) (SEQ ID NO: 37), PTHrP (5-36) (SEQ ID NO: 38), PTH (5-34) (SEQ ID NO: 39), PTHrP (5-34) (SEQ ID NO: 40), PTH (7-84) (SEQ ID NO: 12), PTHrP (7-139) (SEQ ID NO: 41), PTHrP (4-141) (SEQ ID NO: 42), or PTHrP (7-173) (SEQ ID NO: 43)

20

- 30 -

36. The method of claim 1, wherein said nucleic acid molecule is one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, or a fragment thereof.

5 37. A composition comprising a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule encapsulated within a liposome, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of
10 cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth.

38. The method of claim 37, wherein said nucleic acid molecule is contained within a porous biocompatible matrix.


15 39. A composition comprising a proliferation-inducing amount of a nucleic acid molecule encapsulated within a liposome, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro of cultured human
20 keratinocytes by PTH (1-34), $1,25(\text{OH})_2\text{D}_3$ or PTHrP (1-34), or *in vivo* in mouse skin by stimulating skin cell proliferation or accelerating hair cycle progression or stimulating hair cell growth.

25 40. A composition comprising a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule and an active vitamin D compound, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity

- 31 -




with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of inhibiting proliferation or enhancing differentiation *in vitro* of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth.

- 5 41. The composition of claim 40, wherein at least one of said nucleic acid molecules or active vitamin D compound is encapsulated by liposomes.

FIG. 1

2/11

PTHrP cDNA structure

FIG. 2AFIG. 2BFIG 2C.

(Met - (-1AA) precursor peptide)

FIG. 3




FIG. 4

SEQ ID NO: 1 - Human Parathyroid Hormone Coding Sequence (hPTH)

TCTGTGAGTGAAATACAGCTTATGCATAACCTGGGAAAACATCTGAACTC
GATGGAGAGAGTAGAATGGCTGCGTAAGAAGCTGCAGGATGTGCACAATT
TTGTTGCCCTTGGAGCTCCTCTAGCTCCCAGAGATGCTGGTTCCCAGAGG
CCCCGAAAAAAGGAAGACAATGTCTTGGTTGAGAGCCATGAAAAAAGTCT
TGGAGAGGCAGACAAAGCTGATGTGAATGTATTAATAAGCTAAATCCC
AGTGA

FIG. 5

SEQ ID NO: 2 - Bovine Parathyroid Hormone Coding Sequence (bPTH)

GCTGTGAGTGAAATACAGTTTATGCATAACCTGGGCAAACATCTGAGCTC
CATGGAAAGAGTGGAATGGCTGCGGAAAAAGCTACAGGATGTGCACAAC
TTGTTGCCCTTGGAGCTTCTATAGCTTACAGAGATGGTAGTTCCCAGAGA
CCTCGAAAAAAGGAAGACAATGTCTTGGTTGAGAGCCATCAGAAAAGTCT
TGGAGAAGCAGACAAAGCTGATGTGGATGTATTAATTAAAGCTAAACCCC
AG

FIG. 6

SEQ ID NO: 3 - Human Parathyroid Hormone Related Protein Coding Sequence (PTHrP)

GCTGTGTCTGAACATCAGCTCCTCCATGACAAGGGGAAGTCCATCCAAGA
TTTACGGCGACGATTCTTCCTTCACCATCTGATCGCAGAAATCCACACAG
CTGAAATCAGAGCTACCTCGGAGGTGTCCCCTAACTCCAAGCCCTCTCCC
AACACAAAGAACCACCCCGTCCGATTTGGGTCTGATGATGAGGGCAGATA
CCTAACTCAGGAACTAACAAGGTGGAGACGTACAAAGAGCAGCCGCTCA
AGACACCTGGGAAGAAAAAGAAAGGCAAGCCCGGGAACGCAAGGAGCAG
GAAAAGAAAAAACGGCGAACTCGCTCTGCCTGGTTAGACTCTGGAGTGAC
TGGGAGTGGGCTAGAAGGGGACCACCTGTCTGACACCTCCACAACGTTCG
TGGAGCTCGATTACGGAGGCATTGA

FIG. 7

SEQ ID NO: 4 - Rat Parathyroid Hormone Coding Sequence (rPTH)

GCTGTCACTGAAATACAGCTTATGCACAACCTGGGCAAACACCTGGCCTC
TGTGGAGAGGATGCAATGGCTGAGAAAAAAGCTGCAAGATGTACACAATT
TTGTTAGTCTTGGAGTCCAAATGGCTGCCAGAGAAGGCAGTTACCAGAGG
CCCACCAAGAAGGAGGAAAAATGTCCTTGTTGATGGCAATTCAAAAAGTCT
TGGCGAGGGGGACAAAGCTGATGTGGATGTATTAGTTAAGGCTAAATCTC
AGTAA

FIG. 8

SEQ ID NO: 5 - hPTH (1-31) :

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDV

FIG. 9

SEQ ID NO:6 - PTHrP - (1-40)

H₂N-Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-
Leu-Arg-Arg-Arg-Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-
Glu-Ile-Arg-Ala-Thr-Ser-OH

FIG. 10

SEQ ID NO:7 - PTH, Bovine (bPTH) (84 amino acids)

H₂N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-
Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-
Val-Ala-Leu-Gly-Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-
Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-Lys-Ser-Leu-Gly-
Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-Leu-Ile-Lys-Ala-Lys-Pro-Gln-OH

FIG. 11

SEQ ID NO:8 - [Tyr⁶³]-hPTH (63-84)

H₂N-Tyr-Glu-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-
Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-OH

FIG. 12

SEQ ID NO:9 - hPTH (64-84)

H₂N-Glu-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-
Ala-Lys-Ser-Gln-OH

FIG. 13

SEQ ID NO:10 - [Tyr⁶⁹]-hPTH (69-84)

H₂N-Tyr-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-OH

FIG. 14

SEQ ID NO:11 - hPTH (70-84)

H₂N -Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-OH

FIG. 15

SEQ ID NO:12 - hPTH (7-84)

H₂N-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-
Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-
Leu-Ala-Pro-Arg-Asp-Ala-Gly-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-
Val-Leu-Val-Glu-Ser-His-Glu-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-
Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-OH

FIG. 16

SEQ ID NO:13 - hPTHrP (1-31)-

AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIH

FIG. 17

SEQ ID NO:14 - hPTH (1-34)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF

FIG. 18

SEQ ID NO:15 - hPTH (84 amino acids)

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-
Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-
Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg-Asp-Ala-Gly-Ser-Gln-Arg-Pro-
Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Glu-Lys-Ser-Leu-Gly-
Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-
OH (Kimura, T. et al, (1983) BBRC 114493; Fairwell, T. et al, (1983)
Biochemistry 222691)

FIG. 19

SEQ ID NO:16 - Rat PTH (rPTH) (84 amino acids)

H₂N-Ala-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ala-Ser-Val-Glu-Arg-Met-Gln-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ser-Leu-Gly-Val-Gln-Met-Ala-Ala-Arg-Glu-Gly-Ser-Tyr-Gln-Arg-Pro-Thr-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Asp-Gly-Asn-Ser-Lys-Ser-Leu-Gly-Glu-Gly-Asp-Lys-Ala-Asp-Val-Asp-Val-Leu-Val-Lys-Ala-Lys-Ser-Gln-OH (Heinrich, G. et al, (1984) J. Biol. Chem. 2593320)

FIG. 20

SEQ ID NO:17 - bPTH (1-34)

H₂N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (Tregear, G. W. et al, (1977) Biochemistry 162817)

FIG. 21

SEQ ID NO:18 - hPTH (1-34)

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (Takel, T. et al, (1979) Peptide Chemistry)

FIG. 22

SEQ ID NO:19 - [Tyr¹]-hPTH (1-34)

H₂N-Tyr-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH

FIG. 23

SEQ ID NO:20 - hPTH (1-38)

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-OH (Heech, R. D. et al, (1984) Horm. Metab. Res. 16:556)

FIG. 24

SEQ ID NO:21 - bPTH (3-34)

H₂N-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (Lowrik, C. et al, (1985) Cell Calcium 6:311)

FIG. 25

SEQ ID NO:22 - hPTH (13-34)

H₂N-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH

FIG. 26

SEQ ID NO:23 - [Tyr²⁷]-hPTH (27-28)

H₂N-Tyr-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg-Asp-Ala-Gly-Ser-OH

FIG. 27

SEQ ID NO:24 - hPTH (28-48)

H₂N-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg-Asp-Ala-Gly-Ser-OH Rosenblatt, M. et al, (1977) Biochemistry 16:2811)

FIG. 28

SEQ ID NO:25 - hPTH (53-84)

H₂N-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Glu-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-OH (Rosenblatt, M. et al, (1978) Endocrinology 103:976)

FIG. 29

SEQ ID NO: 26 - Oligo -
5'-AGCGGAGACGATGCAGCGGAGA-3'

FIG. 30

SEQ ID NO: 27 - Oligo -
5'-AAGGGAGGCAGCTGAGACG-3'

FIG. 31

SEQ ID NO: 28 - Oligo -
5'-GTCCTTGGAAGGTCTCTGCTG-3'

FIG. 32

SEQ ID NO: 29 - Oligo -
5'-TTCTAGTGCCACTGCCCATTG-3'

FIG. 33

SEQ ID NO: 30 - Oligo -
5'-CTACTAAGCTGTGTGGATTTCTGCGAT-3'

FIG. 34

SEQ ID NO: 31 - hPTHrP (1-34)-
AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHAE

FIG. 35

SEQ ID NO: 32 - hPTHrP (1-141) -
AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHAEIRATSEVSPNSKPSNPNTKNHPVRFSGSDDEGR
YLTQETNKVETYKEQPLKTPGKKKKKGKPGKRKEQEKKRRTRSAWLDSGVTGSGLEGD
HLSDTSTTSLELDSRRH

FIG. 36

SEQ ID NO: 33 - hPTHrP (1-139) -
AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHAEIRATSEVSPNSKPSNPNTKNHPVRFSGSDDEGR
YLTQETNKVETYKEQPLKTPGKKKKKGKPGKRKEQEKKRRTRSAWLDSGVTGSGLEGD
HLSDTSTTSLELDSR

FIG. 37

SEQ ID NO: 34 - hPTHrP (1-173) -
Met-Gln-Arg-Arg-Leu-Val-Gln-Gln-Trp-Ser-Val-Ala-Val-Phe-Leu
Leu-Ser-Tyr-Ala-Val-Pro-Ser-Cys-Gly-Arg-Ser-Val-Glu-Gly-Leu
Ser-Arg-Arg-Leu-Lys-Arg-Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His
Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Phe-Phe-Leu
His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-Glu-Ile-Arg-Ala-Thr

Ser-Glu-Val-Ser-Pro-Asn-Ser-Lys-Pro-Ser-Pro-Asn-Thr-Lys-Asn
His-Pro-Val-Arg-Phe-Gly-Ser-Asp-Asp-Glu-Gly-Arg-Tyr-Leu-Thr
Gln-Glu-Thr-Asn-Lys-Val-Glu-Thr-Tyr-Lys-Glu-Gln-Pro-Leu-Lys
Thr-Pro-Gly-Lys-Lys-Lys-Lys-Gly-Lys-Pro-Gly-Lys-Arg-Lys-Glu
Gln-Glu-Lys-Lys-Lys-Arg-Arg-Thr-Arg-Ser-Ala-Trp-Leu-Asp-Ser
Gly-Val-Thr-Gly-Ser-Gly-Leu-Glu-Gly-Asp-His-Leu-Ser-Asp-Thr
Ser-Thr-Thr-Ser-Leu-Glu-Leu-Asp-Ser-Arg-Thr-Ala-Leu-Leu-Trp
Gly-Leu-Lys-Lys-Lys-Lys-Glu-Asn-Asn-Arg-Arg-Thr-His-His-Met
Gln-Leu-Met-Ile-Ser-Leu-Phe-Lys-Ser-Pro-Leu-Leu-Leu-Leu-End

FIG. 38

SEQ ID NO: 35 - hPTH (7-34) -
LMHNLGKHLNSMERVEWLRKKLQDVHNF

Fig 39

SEQ ID NO: 36 - hPTHrP (7-34) -
LLHDKGKSIQDLRRRFFLHHLIAEIHAE

Fig 40

SEQ ID NO: 37 - hPTH (5-36) -
IQLMHNLGKHLNSMERVEWLRKKLQDVHNFVA

FIG. 41

SEQ ID NO: 38 - hPTHrP (5-36)
H₂N-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-
Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-Glu-Ile -OH

FIG. 42

SEQ ID NO: 39 - hPTH (5-34)
H₂N-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-
Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH

FIG. 43

SEQ ID NO: 40 - hPTHrP (5-34)
H₂N-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-
Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-OH

FIG. 44

SEQ ID NO: 41 - hPTHrP (7-139) -
LLHDKGKSIQDLRRRFFLHHLIAEIHAEIRATSEVSPNSKPSNTKNHPVRFSGDDEGR
YLTQETNKVETYKEQPLKTPGKKKKGKPGKRKEQEKKKRRTRSAWLDSGVTGSGLEGD
HLSDTSTTSLELDSR

FIG. 45

SEQ ID NO: 42 - hPTHrP (7-141) -
LLHDKGKSIQDLRRRFFLHHLIAEIHTAEIRATSEVSPNSKPSNTKNHPVRFSGSDDEGR
YLTQETNKKVETYKEQPLKTPGKKKKGKPGKRKEQEKKKRRTRSAWLDSGVTGSGLEGD
HLSDTSTTSLELDSRRH

FIG. 46

SEQ ID NO: 43 - hPTHrP (7-173) -
Gln-Gln-Trp-Ser-Val-Ala-Val-Phe-Leu
Leu-Ser-Tyr-Ala-Val-Pro-Ser-Cys-Gly-Arg-Ser-Val-Glu-Gly-Leu
Ser-Arg-Arg-Leu-Lys-Arg-Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His
Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Phe-Phe-Leu
His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-Glu-Ile-Arg-Ala-Thr
Ser-Glu-Val-Ser-Pro-Asn-Ser-Lys-Pro-Ser-Pro-Asn-Thr-Lys-Asn
His-Pro-Val-Arg-Phe-Gly-Ser-Asp-Asp-Glu-Gly-Arg-Tyr-Leu-Thr
Gln-Glu-Thr-Asn-Lys-Val-Glu-Thr-Tyr-Lys-Glu-Gln-Pro-Leu-Lys
Thr-Pro-Gly-Lys-Lys-Lys-Lys-Gly-Lys-Pro-Gly-Lys-Arg-Lys-Glu
Gln-Glu-Lys-Lys-Lys-Arg-Arg-Thr-Arg-Ser-Ala-Trp-Leu-Asp-Ser
Gly-Val-Thr-Gly-Ser-Gly-Leu-Glu-Gly-Asp-His-Leu-Ser-Asp-Thr
Ser-Thr-Thr-Ser-Leu-Glu-Leu-Asp-Ser-Arg-Thr-Ala-Leu-Leu-Trp
Gly-Leu-Lys-Lys-Lys-Lys-Glu-Asn-Asn-Arg-Arg-Thr-His-His-Met
Gln-Leu-Met-Ile-Ser-Leu-Phe-Lys-Ser-Pro-Leu-Leu-Leu-Leu-End

FIG. 47

SEQ ID NO: 44 - hPTH (1-44)
H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-
Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-
Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg-OH (Kimura T. et al, (1981)
Biopolymers 20:1823)

-1-

SEQUENCE LISTING

<110> Holick, Michael F.

<120> Regulation of Cell Proliferation And Differentiation Using Topically Applied Nucleic Acid Molecules

<130> 1539.032PC00

<140>

<141>

<150> US 60/238,134

<151> 2000-10-06

<160> 44

<170> PatentIn version 3.0.

<210> 1

<211> 255

<212> DNA

<213> Human Parathyroid Hormone Coding Sequence (hPTH)

<400> 1

tctgtgagtg aaatacagct tatgcataac ctgggaaaac atctgaactc gatggagaga	60
gtagaatggc tgcgtaagaa gctgcaggat gtgcacaatt ttgttgccct tggagctcct	120
ctagctccca gagatgctgg ttcccagagg ccccgaaaaa aggaagacaa tgtccttggtt	180
gagagccatg aaaaaagtct tggagaggca gacaaagctg atgtgaatgt attaactaaa	240
gctaaatccc agtga	255

<210> 2

<211> 252

<212> DNA

<213> Bovine Parathyroid Hormone Coding Sequence (bPTH)

<400> 2

gctgtgagtg aaatacagtt tatgcataac ctgggcaaac atctgagctc catggaaaga	60
gtggaatggc tgcggaaaaa gctacaggat gtgcacaact ttgttgccct tggagcttct	120
atagcttaca gagatggtag ttcccagaga cctcgaaaaa aggaagacaa tgtccttggtt	180
gagagccatc agaaaagtct tggagaagca gacaaagctg atgtggatgt attaattaaa	240
gctaaacccc ag	252

<210> 3

<211> 426

<212> DNA

<213> Human Parathyroid Hormone Related Protein Coding Sequence (PTHrP)

<400> 3

gctgtgtctg aacatcagct cctccatgac aaggggaagt ccatccaaga ttacggcgca	60
---	----

-2-

cgattcttcc ttcaccatct gatcgagaa atccacacag ctgaaatcag agctacctcg 120
gaggtgtccc ctaactccaa gccctctccc aacacaaaga accaccccgt ccgatttggg 180
tctgatgatg agggcagata cctaactcag gaaactaaca aggtggagac gtacaaagag 240
cagccgctca agacacctgg gaagaaaaag aaaggcaagc ccgggaaacg caaggagcag 300
gaaaagaaaa aacggcgaac tcgctctgcc tggtagact ctggagtgcac tgggagtggg 360
ctagaagggg accacctgtc tgacacctcc acaacgtcgc tggagctcga ttcacggagg 420
cattga 426

<210> 4
<211> 255
<212> DNA
<213> Rat Parathyroid Hormone Coding Sequence (rPTH)

<400> 4
gctgtcagtg aaatacagct tatgcacaac ctgggcaaac acctggcctc tgtggagagg 60
atgcaatggc tgagaaaaaa gctgcaagat gtacacaatt ttgttagtct tggagtccaa 120
atggctgcca gagaaggcag ttaccagagg ccaccaaga aggaggaaaa tgccttgtt 180
gatggcaatt caaaaagtct tggcgagggg gacaaagctg atgtggatgt attagttaag 240
gctaaatctc agtaa 255

<210> 5
<211> 30
<212> PRT
<213> hPTH (1-31)

<400> 5
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Leu Gln Asp Val
20 25 30

<210> 6
<211> 40
<212> PRT
<213> PTHrP - (1-40)

<400> 6
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15
Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
20 25 30
Thr Ala Glu Ile Arg Ala Thr Ser
35 40

<210> 7
<211> 84

-3-

<212> PRT
 <213> bPTH

<400> 7
 Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
 1 5 10 15
 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30
 Asn Phe Val Ala Leu Gly Ala Ser Ile Ala Tyr Arg Asp Gly Ser Ser
 35 40 45
 Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Gln
 50 55 60
 Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ile Lys
 65 70 75 80
 Ala Lys Pro Gln

<210> 8
 <211> 22
 <212> PRT
 <213> [Tyr⁶³] hPTH (63-84)

<400> 8
 Tyr Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu
 1 5 10 15
 Thr Lys Ala Lys Ser Gln
 20

<210> 9
 <211> 21
 <212> PRT
 <213> hPTH (64-84)

<400> 9
 Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr
 1 5 10 15
 Lys Ala Lys Ser Gln
 20

<210> 10
 <211> 16
 <212> PRT
 <213> [Tyr⁶⁹] hPTH (69-84)

<400> 10
 Tyr Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln
 1 5 10 15

<210> 11
 <211> 15
 <212> PRT
 <213> hPTH (70-84)

-4-

<400> 11

Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln
 1 5 10 15

<210> 12

<211> 78

<212> PRT

<213> hPTH (7-84)

<400> 12

Leu Met His Asn Leu Gly Lys His Leu Asn Ser Met Glu Arg Val Glu
 1 5 10 15

Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Phe Val Ala Leu Gly
 20 25 30

Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gln Arg Pro Arg Lys Lys
 35 40 45

Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala
 50 55 60

Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln
 65 70 75

<210> 13

<211> 32

<212> PRT

<213> hPTHrP (1-31)

<400> 13

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
 1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
 20 25 30

<210> 14

<211> 34

<212> PRT

<213> hPTH (1-34)

<400> 14

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
 1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30

Asn Phe

<210> 15

<211> 84

<212> PRT

<213> hPTH

<400> 15

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn

1					5					10					15				
Ser	Met	Glu	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His				
			20				25						30						
Asn	Phe	Val	Ala	Leu	Gly	Ala	Pro	Leu	Ala	Pro	Arg	Asp	Ala	Gly	Ser				
		35					40				45								
Gln	Arg	Pro	Arg	Lys	Lys	Glu	Asp	Asn	Val	Leu	Val	Glu	Ser	His	Glu				
		50				55					60								
Lys	Ser	Leu	Gly	Glu	Ala	Asp	Lys	Ala	Asp	Val	Asn	Val	Leu	Thr	Lys				
65				70						75				80					
Ala	Lys	Ser	Gln																

```

<400>      16
Ala Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Ala
1          5          10          15

Ser Val Glu Arg Met Gln Trp Leu Arg Lys Lys Leu Gln Asp Val His
20          25          30          35

Asn Phe Val Ser Leu Gly Val Gln Met Ala Ala Arg Glu Gly Ser Tyr
35          40          45          50

Gln Arg Pro Thr Lys Lys Glu Asp Asn Val Leu Val Asp Gly Asn Ser
50          55          60          65

Lys Ser Leu Gly Glu Gly Asp Lys Ala Asp Val Asp Val Leu Val Lys
65          70          75          80

Ala Lys Ser Gln

```

```

<400> 17
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1          5          10          15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
          20          25          30
Asn Phe

```

<400> 18

-6-

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 19
<211> 34
<212> PRT
<213> [Tyr¹] hPTH (1-34)

<400> 19
Tyr Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 20
<211> 38
<212> PRT
<213> hPTH (1-38)

<400> 20
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe Val Ala Leu Gly
35

<210> 21
<211> 32
<212> PRT
<213> bPTH (3-34)

<400> 21
Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser Ser Met
1 5 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Phe
20 25 30

<210> 22
<211> 22
<212> PRT
<213> hPTH (13-34)

<400> 22
Lys His Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu
1 5 10 15

-7-

Gln Asp Val His Asn Phe
20

<210> 23
<211> 22
<212> PRT
<213> [Tyr²⁷] hPTH (27-28)

<400> 23
Tyr Leu Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala
1 5 10 15

Pro Arg Asp Ala Gly Ser
20

<210> 24
<211> 21
<212> PRT
<213> hPTH (28-48)

<400> 24
Leu Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro
1 5 10 15

Arg Asp Ala Gly Ser
20

<210> 25
<211> 32
<212> PRT
<213> hPTH (53-84)

<400> 25
Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly
1 5 10 15

Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln
20 25 30

<210> 26
<211> 22
<212> DNA
<213> Oligonucleotide

<400> 26
agcggagacg atgcagcgga ga

22

<210> 27
<211> 19
<212> DNA
<213> Oligonucleotide

<400> 27
aaggaggca gctgagacg

19

<210> 28

-8-

<211> 21
 <212> DNA
 <213> Oligonucleotide

<400> 28
 gtccttgga ggtctctgct g 21

<210> 29
 <211> 21
 <212> DNA
 <213> Oligonucleotide

<400> 29
 ttctagtgcc actgcccatt g 21

<210> 30
 <211> 27
 <212> DNA
 <213> Oligonucleotide

<400> 30
 ctactaagct gtgtggattt ctgcgat 27

<210> 31
 <211> 35
 <212> PRT
 <213> hPTHrP (1-34)

<400> 31
 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
 1 5 10 15
 Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
 20 25 30
 Thr Ala Glu
 35

<210> 32
 <211> 141
 <212> PRT
 <213> hPTHrP (1-141)

<400> 32
 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
 1 5 10 15
 Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
 20 25 30
 Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser Lys Pro
 35 40 45
 Ser Pro Asn Thr Lys Asn His Pro Val Arg Phe Gly Ser Asp Asp Glu
 50 55 60
 Gly Arg Tyr Leu Thr Gln Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu
 65 70 75 80

-9-

Gln Pro Leu Lys Thr Pro Gly Lys Lys Lys Lys Gly Lys Pro Gly Lys
 85 90 95

Arg Lys Glu Gln Glu Lys Lys Lys Arg Arg Thr Arg Ser Ala Trp Leu
 100 105 110

Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp His Leu Ser Asp
 115 120 125

Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg Arg His
 130 135 140

<210> 33
 <211> 139
 <212> PRT
 <213> hPTHrP (1-139)

<400> 33
 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
 1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
 20 25 30

Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser Lys Pro
 35 40 45

Ser Pro Asn Thr Lys Asn His Pro Val Arg Phe Gly Ser Asp Asp Glu
 50 55 60

Gly Arg Tyr Leu Thr Gln Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu
 65 70 75 80

Gln Pro Leu Lys Thr Pro Gly Lys Lys Lys Lys Gly Lys Pro Gly Lys
 85 90 95

Arg Lys Glu Gln Glu Lys Lys Lys Arg Arg Thr Arg Ser Ala Trp Leu
 100 105 110

Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp His Leu Ser Asp
 115 120 125

Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg
 130 135

<210> 34
 <211> 209
 <212> PRT
 <213> hPTHrP (1-173)

<400> 34
 Met Gln Arg Arg Leu Val Gln Gln Trp Ser Val Ala Val Phe Leu Leu
 1 5 10 15

Ser Tyr Ala Val Pro Ser Cys Gly Arg Ser Val Glu Gly Leu Ser Arg
 20 25 30

Arg Leu Lys Arg Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly
 35 40 45

-10-

Lys Ser Ile Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile
 50 55 60
 Ala Glu Ile His Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro
 65 70 75 80
 Asn Ser Lys Pro Ser Pro Asn Thr Lys Asn His Pro Val Arg Phe Gly
 85 90 95
 Ser Asp Asp Glu Gly Arg Tyr Leu Thr Gln Glu Thr Asn Lys Val Glu
 100 105 110
 Thr Tyr Lys Glu Gln Pro Leu Lys Thr Pro Gly Lys Lys Lys Lys Gly
 115 120 125
 Lys Pro Gly Lys Arg Lys Glu Gln Glu Lys Lys Lys Arg Arg Thr Arg
 130 135 140
 Ser Ala Trp Leu Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp
 145 150 155 160
 His Leu Ser Asp Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg Thr
 165 170 175
 Ala Leu Leu Trp Gly Leu Lys Lys Lys Lys Glu Asn Asn Arg Arg Thr
 180 185 190
 His His Met Gln Leu Met Ile Ser Leu Phe Lys Ser Pro Leu Leu Leu
 195 200 205

Leu

<210> 35
 <211> 28
 <212> PRT
 <213> hPTH (7-34)

<400> 35
 Leu Met His Asn Leu Gly Lys His Leu Asn Ser Met Glu Arg Val Glu
 1 5 10 15
 Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Phe
 20 25

<210> 36
 <211> 29
 <212> PRT
 <213> hPTHrP (7-34)

<400> 36
 Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg Arg Arg Phe
 1 5 10 15
 Phe Leu His His Leu Ile Ala Glu Ile His Thr Ala Glu
 20 25

<210> 37
 <211> 32
 <212> PRT
 <213> hPTH (5-36)

-11-

<400> 37

Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn Ser Met Glu Arg
 1 5 10 15

Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Phe Val Ala
 20 25 30

<210> 38

<211> 32

<212> PRT

<213> hPTHrP (5-36)

<400> 38

His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg Arg
 1 5 10 15

Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His Thr Ala Glu Ile
 20 25 30

<210> 39

<211> 30

<212> PRT

<213> hPTH (5-34)

<400> 39

Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn Ser Met Glu Arg
 1 5 10 15

Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Phe
 20 25 30

<210> 40

<211> 30

<212> PRT

<213> hPTHrP (5-34)

<400> 40

His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg Arg
 1 5 10 15

Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His Thr Ala
 20 25 30

<210> 41

<211> 133

<212> PRT

<213> hPTHrP (7-139)

<400> 41

Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg Arg Arg Phe
 1 5 10 15

Phe Leu His His Leu Ile Ala Glu Ile His Thr Ala Glu Ile Arg Ala
 20 25 30

Thr Ser Glu Val Ser Pro Asn Ser Lys Pro Ser Pro Asn Thr Lys Asn
 35 40 45

His Pro Val Arg Phe Gly Ser Asp Asp Glu Gly Arg Tyr Leu Thr Gln
 50 55 60

-12-

Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu Gln Pro Leu Lys Thr Pro
 65 70 75 80
 Gly Lys Lys Lys Lys Gly Lys Pro Gly Lys Arg Lys Glu Gln Glu Lys
 85 90 95
 Lys Lys Arg Arg Thr Arg Ser Ala Trp Leu Asp Ser Gly Val Thr Gly
 100 105 110
 Ser Gly Leu Glu Gly Asp His Leu Ser Asp Thr Ser Thr Thr Ser Leu
 115 120 125
 Glu Leu Asp Ser Arg
 130

<210> 42
 <211> 135
 <212> PRT
 <213> hPTHrP (7-141)

<400> 42
 Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg Arg Arg Phe
 1 5 10 15
 Phe Leu His His Leu Ile Ala Glu Ile His Thr Ala Glu Ile Arg Ala
 20 25 30
 Thr Ser Glu Val Ser Pro Asn Ser Lys Pro Ser Pro Asn Thr Lys Asn
 35 40 45
 His Pro Val Arg Phe Gly Ser Asp Asp Glu Gly Arg Tyr Leu Thr Gln
 50 55 60
 Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu Gln Pro Leu Lys Thr Pro
 65 70 75 80
 Gly Lys Lys Lys Lys Gly Lys Pro Gly Lys Arg Lys Glu Gln Glu Lys
 85 90 95
 Lys Lys Arg Arg Thr Arg Ser Ala Trp Leu Asp Ser Gly Val Thr Gly
 100 105 110
 Ser Gly Leu Glu Gly Asp His Leu Ser Asp Thr Ser Thr Thr Ser Leu
 115 120 125
 Glu Leu Asp Ser Arg Arg His
 130 135

<210> 43
 <211> 203
 <212> PRT
 <213> hPTHrP (7-173)

<400> 43
 Gln Gln Trp Ser Val Ala Val Phe Leu Leu Ser Tyr Ala Val Pro Ser
 1 5 10 15
 Cys Gly Arg Ser Val Glu Gly Leu Ser Arg Arg Leu Lys Arg Ala Val
 20 25 30
 Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu

-13-

35					40					45					
Arg	Arg	Arg	Phe	Phe	Leu	His	His	Leu	Ile	Ala	Glu	Ile	His	Thr	Ala
50						55					60				
Glu	Ile	Arg	Ala	Thr	Ser	Glu	Val	Ser	Pro	Asn	Ser	Lys	Pro	Ser	Pro
65					70					75					80
Asn	Thr	Lys	Asn	His	Pro	Val	Arg	Phe	Gly	Ser	Asp	Asp	Glu	Gly	Arg
				85					90					95	
Tyr	Leu	Thr	Gln	Glu	Thr	Asn	Lys	Val	Glu	Thr	Tyr	Lys	Glu	Gln	Pro
			100					105					110		
Leu	Lys	Thr	Pro	Gly	Lys	Lys	Lys	Lys	Gly	Lys	Pro	Gly	Lys	Arg	Lys
			115					120				125			
Glu	Gln	Glu	Lys	Lys	Lys	Arg	Arg	Thr	Arg	Ser	Ala	Trp	Leu	Asp	Ser
			130			135					140				
Gly	Val	Thr	Gly	Ser	Gly	Leu	Glu	Gly	Asp	His	Leu	Ser	Asp	Thr	Ser
145					150					155					160
Thr	Thr	Ser	Leu	Glu	Leu	Asp	Ser	Arg	Thr	Ala	Leu	Leu	Trp	Gly	Leu
				165					170					175	
Lys	Lys	Lys	Lys	Glu	Asn	Asn	Arg	Arg	Thr	His	His	Met	Gln	Leu	Met
				180				185					190		
Ile	Ser	Leu	Phe	Lys	Ser	Pro	Leu	Leu	Leu	Leu					
				195			200								

<210> 44
 <211> 44
 <212> PRT
 <213> hPTH (1-44)

<400> 44
 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
 1 5 10 15
 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30
 Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg
 35 40

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/028420 A2

(51) International Patent Classification⁷: A61K 38/29,
31/7088, 48/00, C12N 5/08, A61K 9/127, 7/06, 7/48,
A61P 17/00, 35/00 // (A61K 38/29, 31:59)

(81) Designated States (*national*): AU, CA, JP, KR, US.

(21) International Application Number: PCT/US01/31082

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(22) International Filing Date: 5 October 2001 (05.10.2001)

Published:

(25) Filing Language: English

— without international search report and to be republished upon receipt of that report

(26) Publication Language: English

(30) Priority Data:
60/238,134 6 October 2000 (06.10.2000) US

(48) Date of publication of this corrected version:

20 February 2003

(71) Applicant and

(15) Information about Correction:

(72) Inventor: HOLICK, Michael, F. [US/US]; 31 Bishop Lane, Sudbury, MA 01776 (US).

see PCT Gazette No. 08/2003 of 20 February 2003, Section II

(74) Agents: ESMOND, Robert, W. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, DC 20005-3934 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REGULATION OF CELL PROLIFERATION AND DIFFERENTIATION USING TOPICALLY APPLIED NUCLEIC ACID MOLECULES

(57) Abstract: Methods are disclosed for the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorder, such as psoriasis, and skin cancer for enhancing wound healing, for stimulating hair growth and inhibiting hair growth, by administration of nucleic acid molecules encoding parathyroid hormone (PTH), parathyroid related peptide (PTHrP), or fragment, analog or derivative thereof, and salts thereof, encapsulated by particular liposomes or incorporated into a porous biocompatible matrix.

WO 02/028420 A2

Regulation Of Cell Proliferation And Differentiation Using Topically Applied Nucleic Acid Molecules

Background of the Invention

Field of the Invention

5 This invention relates to the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorder, such as psoriasis, for enhancing wound healing, for stimulating hair growth, and inhibiting hair growth by topical administration of nucleic acid molecules encoding parathyroid hormone (PTH), parathyroid related peptide (PTHrP), or
10 a fragment or analog thereof.

Related Art

 U.S. Pat. Nos. 5,527,772, 5,840,690 and 6,066,618 describe methods of inhibiting proliferation and enhancing differentiation of mammalian cells, inducing proliferation of mammalian cells, enhancing wound healing, and
15 stimulating hair growth using a peptide which has a 10% or greater homology to a region of human PTH or human PTHrP. Certain fragments and analogs (e.g. PTH (1-34), PTH (3-34) and PTHrP (1-34)) were found to act as agonists of PTH and PTHrP and inhibit proliferation and enhance differentiation of mammalian cells. Other fragments and analogs (e.g. PTH (7-34) and PTHrP
20 (7-34) are antagonists of PTH and PTHrP were also found to enhance the proliferation of mammalian cells. The agonists are useful for treatment of hyperproliferative skin diseases such a psoriasis, actinic keratoses, and skin cancer and the antagonists are useful for wound healing, particularly wounds of the skin, enhancing or maintaining hair growth, particularly following
25 chemotherapeutic treatment of a mammal, and stimulating epidermal regrowth. Methods of administration include oral, nasal, intravenous, topical, subcutaneous, parenteral and intraperitoneal administration. The peptides may

- 2 -

be administered by subcutaneous pumps, patches, tapes, or by liposomal carriers.

A variety of PTH and PTHrP analogs and derivatives thereof have been made. See U.S. Pat. Nos. 4,086,196, 4,423,037, 4,771,124, 4,833,125, 4,968,669, 5,001,223, 5,087,562, 5,093,233, 5,116,952, 5,149,779, 5,171,670, 5,229,489, 5,317,010, 5,382,658, 5,393,869, 5,434,246, 5,527,772, 5,589,452, 5,807,823, 5,821,255, 5,840,690, 5,977,070, 6,025,467, 6,051,868, and 6,066,618; WO94/02510, WO00/23594, and WO00/31137; and EP 477,885. Methods for determining whether a particular analog is an agonist or antagonist of PTH and PTHrP are described in U.S. Pat. Nos. 5,527,772, 5,840,690 and 6,066,618.

Active vitamin D compounds are useful for treating hyperproliferative skin diseases and other conditions. A large number of such active vitamin D compounds are known. See U.S. Patent Nos. 5,457,217, 5,414,098, 5,384,313, 5,373,004, 5,371,249, 5,430,196, 5,260,290, 5,393,749, 5,395,830, 5,250,523, 5,247,104, 5,397,775, 5,194,431, 5,281,731, 5,254,538, 5,232,836, 5,185,150, 5,321,018, 5,086,191, 5,036,061, 5,030,772, 5,246,925, 4,973,584, 5,354,744, 4,927,815, 4,857,518, 4,851,401, 4,851,400, 4,847,012, 4,755,329, 4,940,700, 4,619,920, 4,594,192, 4,588,716, 4,564,474, 4,552,698, 4,588,528, 4,719,204, 4,719,205, 4,689,180, 4,505,906, 4,769,181, 4,502,991, 4,481,198, 4,448,726, 4,448,721, 4,428,946, 4,411,833, 4,367,177, 4,336,193, 4,360,472, 4,360,471, 4,307,231, 4,307,025, 4,358,406, 4,305,880, 4,279,826, and 4,248,791.

Summary of the Invention

The invention provides two important therapeutic methods one involving inhibition of cell proliferation and enhancement of skin cell differentiation (the agonist activity), which is useful in the treatment of psoriasis, ichthyosis, actinic keratoses, skin cancer, inhibiting hair growth or preventing hair regrowth. A second method involves enhancement of cell proliferation (the antagonist activity), which is useful in wound healing,

stimulating epidermal regrowth and hair growth. In addition, the invention provides methods for enhancing wound healing and hair growth based on *in vivo* wound healing activity or *in vitro* or *in vivo* hair growth activity rather than strict agonist or antagonist activity *in vitro*.

5 The first method of the invention generally involves inhibiting proliferation and enhancing differentiation of mammalian skin cells by contacting the cell with a nucleic acid molecule encoding a peptide which is preferably at least 3, and more preferably at least 8, amino acids long and has
10 10% or greater (more preferably, 50% or greater, and most preferably 75% or greater) sequence identity with a region (preferably within the amino-terminal 34 amino acid region) of human PTH or human PTHrP and, when expressed, is capable of inhibiting proliferation or enhancing the differentiation *in vitro* of cultured human keratinocytes; or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair growth. In preferred
15 embodiments of this method, the peptide encoded by the nucleic acid molecule is hPTH (1-84), hPTH (1-34), hPTHrP (1-31), hPTHrP (1-40), hPTH (1-44), hPTH (1-36), hPTH (1-38), hPTH (1-31), hPTH (3-34), hPTHrP (1-34), hPTHrP (1-141), hPTHrP (1-139) or hPTHrP (1-173). This method has particular application in the treatment of hyperproliferative skin disorders such
20 as psoriasis. The method may also be useful in the treatment of certain preskin cancers and skin cancers, by the inhibition of cancer cell proliferation and by the induction of differentiation and inhibition of hair growth or preventing hair growth and acne.

25 The second method of the invention generally involves enhancing proliferation of mammalian skin cells by contacting the skin cells with a nucleic acid molecule encoding a peptide which is preferably at least 3, and more preferably at least 8, amino acids long and has 10% or greater (more preferably, 50% or greater, and most preferably 75% or greater) sequence identity with a region (preferably within the amino-terminal 34 amino acid
30 region) of hPTH or hPTHrP and, when expressed, is capable of blocking the differentiation or the inhibition of proliferation *in vitro* of cultured human

keratinocytes by PTH (1-34) or $1,25(\text{OH})_2\text{D}_3$ or PTHrP (1-34); or *in vivo* in mouse skin by stimulating skin cell proliferation or accelerating hair cycle progression or stimulating hair growth. In a preferred embodiment of this method, the peptide encoded by the nucleic acid molecule is PTH (7-34), PTH (7-84), hPTH (5-34), hPTHrP (7-34), hPTHrP (5-34), hPTHrP (7-141), hPTHrP (7-134), or hPTHrP (7-173). In a related method of the invention, proliferation of mammalian skin cells, e.g., during wound healing, is enhanced by contacting the cell or wound with nucleic acid molecule encoding a peptide which is preferably at least 3, and more preferably at least 8, amino acids long and has 10% or greater (more preferably, 50% or greater, and most preferably, 75% or greater) sequence identity with a region (preferably, within the amino-terminal 34 amino acid region) of hPTH or hPTHrP, and, when expressed, is capable of enhancing wound healing in an *in vivo* skin punch assay. In preferred embodiments of this method, the peptide encoded by the nucleic acid molecule is hPTH (1-84), hPTH (1-34), hPTH (7-34), hPTH (5-34), hPTH (5-36), hPTH (1-31), hPTHrP (1-34), hPTHrP (1-135), hPTHrP (1-141), hPTHrP (1-173) or hPTHrP (7-34). These related methods have particular application in the enhancement of wound healing and also have applications in the promotion of skin growth in patients with burns or skin ulcerations as well as in the stimulation of epidermal regrowth in people who have decreased epidermal cell proliferation due to aging.

Hair growth is stimulated by administering to a mammal a nucleic acid molecule encoding a peptide which is preferably at least 3, and more preferably at least 8, amino acids long and has 10% or greater (more preferably, 50% or greater, and most preferably, 75% or greater) sequence identity with a region (preferably, within the amino-terminal 34 amino acid region) of hPTH or hPTHrP, and, when expressed, is capable of stimulating hair growth *in vitro* or *in vivo*. In preferred embodiments of this method, the peptide encoded by the nucleic acid molecule is hPTH (7-34), hPTH (7-84), hPTHrP (7-134), hPTHrP (7-141), hPTHrP (7-173), hPTH (5-34), hPTHrP (7-34) or hPTH (5-36).

The nucleic acid molecules are administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier. In a preferred embodiment, the carrier is a liposome or gel. In another preferred embodiment the nucleic acid molecules are contained within a porous biocompatible matrix.

The invention also relates to a method of inhibiting proliferation or enhancing differentiation of a skin or hair cell of a mammal, comprising administering to the mammal in need thereof a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule of the invention and an active vitamin D compound, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of inhibiting proliferation or enhancing differentiation *in vitro* of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth. The invention also relates to a composition comprising a nucleic acid molecule of the invention encapsulated within a liposome.

The invention also relates to a composition comprising a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule of the invention and an active vitamin D compound, optionally encapsulated within a liposome.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Brief Description of the Figures

FIG. 1 depicts a bar graph showing the effect of transfecting PTHrP (1-141) and PTHrP (1-173) genes into cultured keratinocytes on ³H-thymidine incorporation. Bar 1 represents the empty vector, Bar 2 represents the PTHrP

gene (1-141) transfected into cultured human keratinocytes, Bar 3 represents the PTHrP gene (1-173) transfected into cultured human keratinocytes.

FIGs. 2A-2C depict schematic representations of the cDNA structure of the PTHrP (1-139), PTHrP (1-141) and PTHrP (1-173) genes.

5 FIG. 3 depicts a schematic representation of the pACCMV.pLpa adenoviral expression vector.

FIG. 4 depicts the sequence of SEQ ID NO: 1.

FIG. 5 depicts the sequence of SEQ ID NO: 2.

FIG. 6 depicts the sequence of SEQ ID NO: 3.

10 FIG. 7 depicts the sequence of SEQ ID NO: 4.

FIG. 8 depicts the sequence of SEQ ID NO: 5.

FIG. 9 depicts the sequence of SEQ ID NO: 6.

FIG. 10 depicts the sequence of SEQ ID NO: 7.

FIG. 11 depicts the sequence of SEQ ID NO: 8.

15 FIG. 12 depicts the sequence of SEQ ID NO: 9.

FIG. 13 depicts the sequence of SEQ ID NO: 10.

FIG. 14 depicts the sequence of SEQ ID NO: 11.

FIG. 15 depicts the sequence of SEQ ID NO: 12.

FIG. 16 depicts the sequence of SEQ ID NO: 13.

20 FIG. 17 depicts the sequence of SEQ ID NO: 14.

FIG. 18 depicts the sequence of SEQ ID NO: 15.

FIG. 19 depicts the sequence of SEQ ID NO: 16.

FIG. 20 depicts the sequence of SEQ ID NO: 17.

FIG. 21 depicts the sequence of SEQ ID NO: 18.

25 FIG. 22 depicts the sequence of SEQ ID NO: 19.

FIG. 23 depicts the sequence of SEQ ID NO: 20.

FIG. 24 depicts the sequence of SEQ ID NO: 21.

FIG. 25 depicts the sequence of SEQ ID NO: 22.

FIG. 26 depicts the sequence of SEQ ID NO: 23.

30 FIG. 27 depicts the sequence of SEQ ID NO: 24.

FIG. 28 depicts the sequence of SEQ ID NO: 25.

- 7 -

FIG. 29 depicts the sequence of SEQ ID NO: 26.

FIG. 30 depicts the sequence of SEQ ID NO: 27.

FIG. 31 depicts the sequence of SEQ ID NO: 28.

FIG. 32 depicts the sequence of SEQ ID NO: 29.

5 FIG. 33 depicts the sequence of SEQ ID NO: 30.

FIG. 34 depicts the sequence of SEQ ID NO: 31.

FIG. 35 depicts the sequence of SEQ ID NO: 32.

FIG. 36 depicts the sequence of SEQ ID NO: 33.

FIG. 37 depicts the sequence of SEQ ID NO: 34.

10 FIG. 38 depicts the sequence of SEQ ID NO: 35.

FIG. 39 depicts the sequence of SEQ ID NO: 36.

FIG. 40 depicts the sequence of SEQ ID NO: 37.

FIG. 41 depicts the sequence of SEQ ID NO: 38.

FIG. 42 depicts the sequence of SEQ ID NO: 39.

15 FIG. 43 depicts the sequence of SEQ ID NO: 40.

FIG. 44 depicts the sequence of SEQ ID NO: 41.

FIG. 45 depicts the sequence of SEQ ID NO: 42.

FIG. 46 depicts the sequence of SEQ ID NO: 43.

FIG. 47 depicts the sequence of SEQ ID NO: 44.

20

Description of the Preferred Embodiments

Nucleic Acid Molecules of the Invention

25

The invention relates to the regulation of cell differentiation and proliferation by administration of nucleic acid molecules encoding parathyroid hormone (PTH), parathyroid hormone related protein (PTHrP), or a fragment or analog thereof. Particular nucleic acid molecules which can be used include those which encode the following peptides:

hPTH (1-84), encoded by nucleotides 1-252 of the nucleic acid molecule of SEQ ID NO: 1 (Kimura, T. *et al.*, *BBRC* 11:493 (1983); Fairwell, T. *et al.*, *Biochemistry* 22:691 (1983)).

hPTH (1-31), encoded by nucleotides 1-93 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (1-34), encoded by nucleotides 1-102 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (1-36), encoded by nucleotides 1-108 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (1-38), encoded by nucleotides 1-114 of the nucleic acid molecule of SEQ ID NO:1 (Heech, R. D. *et al.*, *Horm. Metab. Res.* 16:556 (1984)).

hPTH (1-44), encoded by nucleotides 1-132 of the nucleic acid molecule of SEQ ID NO:1 (Kimura T. *et al.*, *Biopolymers* 20:1823 (1981)).

hPTH (5-36), encoded by nucleotides 13-108 of the nucleic acid molecule of SEQ ID NO:1.

hPTH (7-34), encoded by nucleotides 19-102 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (13-34), encoded by nucleotides 40-102 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (28-48), encoded by nucleotides 82-144 of the nucleic acid molecule of SEQ ID NO: 1 (Rosenblatt, M. *et al.*, *Biochemistry* 16:2811 (1977)).

hPTH (7-84), encoded by nucleotides 19-252 of the nucleic acid molecule of SEQ ID NO: 1.

hPTH (53-84), encoded by nucleotides 157-252 of the nucleic acid molecule of SEQ ID NO:1 (Rosenblatt, M. *et al.*, *Endocrinology* 103:976 (1978)).

hPTH (64-84), encoded by nucleotides 190-252 of the nucleic acid molecule of SEQ ID NO:1.

hPTH (70-84), encoded by nucleotides 208-252 of the nucleic acid molecule of SEQ ID NO:1.

[Tyr¹]-hPTH (1-34), encoded by nucleotides 1-102 of the nucleic acid molecule of SEQ ID NO: 1, wherein the adenosine at position 2 is mutated to a cytosine.

[Tyr²⁷]-hPTH (27-48), encoded by nucleotides 79-144 of the nucleic acid molecule of SEQ ID NO: 1, wherein the adenosine at position 79 and the guanosine at position 81 are both mutated to a thymidine.

[Tyr⁶³]-hPTH (63-84), encoded by nucleotides 187-252 of the nucleic acid molecule of SEQ ID NO: 1, wherein the cytosine at position 187 is mutated to a thymidine.

[Tyr⁶⁹]-hPTH (69-84), encoded by nucleotides 205-255 of the nucleic acid molecule of SEQ ID NO: 1, wherein the guanosine at position 205 is mutated to a thymidine, and the guanosine at position 207 is mutated to either a thymidine or a cytosine.

PTH, Bovine (bPTH) (1-84), encoded by nucleotides 1-252 of the nucleic acid molecule of SEQ ID NO: 2.

bPTH (1-34), encoded by nucleotides 1-102 of the nucleic acid molecule of SEQ ID NO: 2 (Tregear, G. W. *et al.*, *Biochemistry* 16:2817 (1977)).

bPTH (3-34), encoded by nucleotides 7-102 of the nucleic acid molecule of SEQ ID NO: 2 (Lowrik, C. *et al.*, *Cell Calcium* 6:311 (1985)).

PTHrP (1-31), encoded by nucleotides 1-93 of the nucleic acid molecule of SEQ ID NO: 3.

PTHrP (1-40), encoded by nucleotides 1-120 of the nucleic acid molecule of SEQ ID NO: 3.

PTHrP (5-36), encoded by nucleotides 13-108 of the nucleic acid molecule of SEQ ID NO: 3.

PTHrP (7-34), encoded by nucleotides 19-102 of the nucleic acid molecule of SEQ ID NO: 3.

PTHrP (7-139), encoded by nucleotides 19-417 of the nucleic acid molecule of SEQ ID NO: 3.

PTHrP (7-141), encoded by nucleotides 19-423 of the nucleic acid molecule of SEQ ID NO: 3.

PTHrP (7-173), encoded by nucleotides 19-519 of the nucleic acid molecule of SEQ ID NO: 3.

Rat PTH (rPTH) (1-84), encoded by nucleotides 1-252 of the nucleic acid molecule of SEQ ID NO: 4 (Heinrich, G. *et al.*, *J. Biol. Chem.* 25:3320 (1984)).

In addition, nucleic acid molecules which encode the peptides and peptide derivatives disclosed in the following documents can also be used: U.S. Pat. Nos. 4,086,196, 4,423,037, 4,771,124, 4,833,125, 4,968,669, 5,001,223, 5,087,562, 5,093,233, 5,116,952, 5,149,779, 5,171,670, 5,229,489, 5,317,010, 5,382,658, 5,393,869, 5,434,246, 5,527,772, 5,589,452, 5,807,823, 5,821,255, 5,840,690, 5,977,070, 6,025,467, 6,051,868, and 6,066,618; WO94/02510, WO00/23594, and WO00/31137; and EP 477,885.

A typical design for constructing the PTH (7-34), (7-84), (7-141), and PTHrP (7-34), (7-139), and (7-173) fragment cDNAs is to place a ATG start codon upstream of the initial peptide codon of the individual fragments and to introduce a stop codon downstream of the final peptide codon of the individual fragments. Also, an endogenous peptide cleavage site will be introduced between the ATG start codon and the initial peptide codon of the individual fragments to avoid unwanted amino acids being introduced into the constructs.

When selecting a candidate nucleic acid molecule for a method of this invention, a preferred first step is to choose a nucleic acid molecule encoding a peptide which includes a fragment which has at least 10%, and more preferably 50% or greater, sequence identity with an 8 or greater amino acid long fragment within the amino terminal 34 amino acid region of hPTH or hPTHrP. The term "sequence identity" refers to a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. (See, *e.g.*: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer*

Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

5 While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in
10 Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG
15 program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(i):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., *et al.*, *J Molec Biol* 215:403 (1990)).

Therefore, as used herein, the term "identity" represents a comparison between a test and reference sequence. More specifically, reference test
20 sequence is defined as any test sequence that is 10% or more identical to a reference sequence. As used herein, the term at least 10% identical to refers to percent identities from 10 to 99.99 relative to the reference sequence. Identity at a level of 10% or more is indicative of the fact that, assuming for exemplification purposes a test and reference sequence length of 100 amino
25 acids, that no more than 90% (i.e., 90 out of 100) of the amino acids in the test sequence differ from that of the reference sequence. Such differences may be represented as point mutations randomly distributed over the entire length of the nucleotide or amino acid sequence of the invention or they may be clustered in one or more locations of varying length up to the maximum
30 allowable amino acid difference. Differences are defined as nucleotide or amino acid substitutions, or deletions.

- 12 -

Because of the high degree of homology among human PTH and PTH of other species, PTH peptides encoded by nucleic acids from non-human as well as human sources can be used. Similarly, human PTHrP (1-139), (1-141) and (1-173) have a high degree of homology with PTHrP of other species; therefore, nucleic acids from non-human as well as human sources can be used in the methods of the invention involving PTHrP.

Candidate nucleic acid molecules may be tested for suitability as inhibitors of cell proliferation and enhancers of differentiation using cultured human keratinocytes, similar to the method for testing peptides described in U.S. Pat. Nos. 5,527,772, 5,840,690 and 6,066,618. Briefly, those nucleic acid molecules encoding peptides which inhibit proliferation and induce differentiation in cultured keratinocytes are those potentially useful as therapeutic agents in treating disorders, e.g., psoriasis and cancer, where suppression of cell proliferation is desired. Candidate nucleic acid molecules may be tested for suitability as enhancers of cell proliferation using cultured human keratinocytes or *in vivo* mouse model. Those peptides encoded by the nucleic acid molecules which block the effect of agonist peptides or 1,25(OH)₂D₃ on cultured keratinocyte proliferation are those potentially useful as therapeutic agents in treating disorders, e.g., wounds, burns, or skin ulcerations, where maintenance or stimulating of cell proliferation is desired.

Candidate nucleic acid molecules may be tested for their ability to enhance wound healing by carrying out a skin punch biopsy test, as described in U.S. Pat. Nos. 5,527,772, 5,840,690 and 6,066,618.

Candidate peptides may be tested for suitability as stimulators of hair growth using an *in vitro* hair growth assay, as described in U.S. Pat. Nos. 5,527,772, 5,840,690 and 6,066,618. Those peptides encoded by the nucleic acid molecules which stimulate hair growth *in vitro* are those potentially useful for the stimulation of hair growth *in vivo*, e.g., for the stimulation or maintenance of hair growth during or following chemotherapy or to treat a form of alopecia, e.g., male and female pattern baldness.

Alternatively, *in vivo* assays may be carried out as described herein and similar to those described in Schilli, M.B. *et al.*, *J. Invest. Dermatol.* 108:928-932 (1997); Holick, M.F., *et al.*, *Proc. Natl. Acad. Sci.* 91:8014-8016 (1994); Paus, R. and Cotsarelis, G., *N. Engl. J. Med.* 341: 491-497 (1999); Paus, R., *et al. Laboratory Invest.* 60: 365-369 (1989) and U.S. Pat. App. No. 60/213,247.

Care should be taken when determining the correct nucleic acid molecule for use in the invention. Experiments have shown that when normal cultured human keratinocytes are transfected with plasmids containing PTHrP (1-141) or PTHrP (1-173) an unexpected enhancement of cell growth is seen, as measured by ³H-thymidine incorporation into epidermal DNA (FIG. 1). These results are attributed to proteolysis of the full-length peptide. For this reason, all candidate nucleic acid molecules should be tested for the expected activity before use.

Gene Therapy

In this preferred embodiment of the invention, a nucleic acid molecule encoding a peptide with desired activity is incorporated into a polynucleotide construct suitable for introducing the nucleic acid molecule into cells of the animal to be treated, to form a transfection vector. The transfection vector is then introduced into selected target tissues of the cells of the animal *in vivo* using any of a variety of methods known to those skilled in the art. Alternatively, naked DNA may be transfected into the cells, with or without cationic lipids.

Techniques for the construction of transfection vectors containing inserts of desired nucleic acid sequences are well-known in the art, and are generally described in "Working Toward Human Gene Therapy," Chapter 28 in *Recombinant DNA, 2nd Ed.*, Watson, J.D. *et al.* (eds.), Scientific American Books: New York (1992), pp. 567-581, or Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, New York (1989).

Gene therapy approaches that may be used to deliver a nucleic acid molecule include injection of plasmid DNA (Horton, H.M., *et al.*, *Proc. Natl. Acad. Sci. USA* 96(4):1553-1558 (1999)); transduction using adenoviral vectors (Waugh, J.M., *et al.*, *Proc. Natl. Acad. Sci. USA* 96(3):1065-1070 (1999)); transduction using retroviral vectors (Axelrod, J.H., *et al.*, *Proc. Natl. Acad. Sci. USA* 87:5173-5177 (1990); Drumm, M.L., *et al.*, *Cell* 62:1227-1233 (1990); Krueger, G.G., *et al.*, *J. Invest. Dermatol.* 112:233-239 (1999); Palmer, T.D., *et al.*, *Blood* 73:438-445 (1989); and Rosenberg, S.A., *et al.*, *N. Eng. J. Med.* 323:570-578 (1990)); and gene transfer using liposomes (Mason, C.A.E., *et al.*, *Nature Medicine* 5(2):176-182 (1999)). In addition, general methods for construction of gene therapy vectors and the introduction of such vectors into a mammal for therapeutic purposes may be obtained in the above-referenced publications, the disclosures of which are specifically incorporated herein by reference in their entirety. In one such general method, vectors containing nucleic acid sequences of the present invention are directly introduced into the cells or tissues of the mammal to be treated, preferably by topical application. Such an approach is generally referred to as "*in vivo*" gene therapy.

Alternatively, cells or tissues may be removed from the mammal to be treated and placed into culture according to methods that are well-known to one of ordinary skill in the art. Transfection vectors or naked DNA containing the genes for desired peptides may then be introduced into these cells or tissues by any of the methods described generally above for introducing isolated polynucleotides into a cell or tissue. After a sufficient amount of time to allow incorporation of the inserted DNA, the cells or tissues may then be re-inserted into the mammal to be treated. Since introduction of the nucleic acid molecule encoding the peptide is performed outside of the body of the mammal, this approach is generally referred to as "*ex vivo*" gene therapy. See U.S. Patent No. 5,399,346. Gene transfer through transfection of cells *ex vivo* can be performed by a variety of methods, including, for example, calcium phosphate precipitation,

diethylaminoethyl dextran, electroporation, lipofection, or viral infection. Such methods are well known in the art (see, for example, Sambrook *et al.*).

For both *in vivo* and *ex vivo* gene therapy, the nucleic acid molecule encoding the desired peptide of the invention may be operatively linked to a regulatory DNA sequence, or "promoter," to form a genetic construct as described above. This construct, containing both the promoter and the nucleic acid molecule encoding the peptide, may be subcloned into a suitable vector such as a plasmid, adenovirus vector, retrovirus vector, or the like, and introduced into the animal to be treated in an *in vivo* gene therapy approach, or into the cells or tissues of the mammal in an *ex vivo* approach.

Alternatively, the nucleic acid molecule of the invention may be operatively linked to a heterologous regulatory DNA sequence, or promoter, to form a genetic construct as described above. The heterologous regulatory sequence may be tissue specific. The vector containing the genetic construct is then directly introduced into the animal to be treated or into the cells or tissues of the animal, as described.

The term "operably linked", as used herein, denotes a relationship between a regulatory region (typically a promoter element, but may include an enhancer element) and the gene, whereby the transcription of the gene is under the control of the regulatory region.

The term "heterologous" means a DNA sequence not found in the native genome. That is, two nucleic acid elements are said to be "heterologous" if the elements are derived from two different genes, or alternatively, two different species. Thus, "heterologous DNA regulatory sequence" indicates that the regulatory sequence is not naturally ligated to the nucleic acid molecule selected for use in the invention.

The term "promoter" is used according to its art-recognized meaning. It is intended to mean the DNA region, usually upstream to the coding sequence of a gene, which binds RNA polymerase and directs the enzyme to the correct transcriptional start site.

- 16 -

In general, a promoter may be functional in a variety of tissue types and in several different species of organisms, or its function may be restricted to a particular species and/or a particular tissue. Further, a promoter may be constitutively active, or it may be selectively activated by certain substances (e.g., a tissue-specific factor), under certain conditions (e.g., in the presence of an enhancer element, if present, in the genetic construct containing the promoter), or during certain developmental stages of the organism (e.g., active in fetus, silent in adult).

Promoters useful in the practice of the present invention are preferably "tissue-specific"--that is, they are capable of driving transcription of a gene in one tissue while remaining largely "silent" in other tissue types. Examples of tissue-specific promoters in the skin are the Keratin promoter (Vassar *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 86:8565 (1989)), the POMC promoter (Deen *et al.* *Mol. Biol. Evol.* 9:483 (1992)), the alpha-actin promoter (Shani, *Mol. Cell Biol.*, 6:2624 (1986)), the elastase-q promoter (Swift *et al.*, *Cell* 28:639 (1984)), the tyrosine hydroxylase promoter (Kim, L. S., *et al.*, *J. Biol. Chem* 268:15689 (1993); Kaneda, N., *et al.*, *Neuron* 6:583 (1991)), the dopamine beta-hydroxylase promoter (Mercer E. H., *et al.*, *Neuron* 7:703 (1991); Hcyle, G. W., *et al.*, *J. Neurosci.* 14:2455 (1994)), the tryptophan hydroxylase promoter (Boularand, S., *et al.*, *J. Biol. Chem* 270:3757 (1995); Stoll, J. and Goldman, D., *J. Neurosci. Res.* 28:457 (1991)) and the parathyroid hormone-related peptide promoter (Campos, R. V., *et al.*, *Mol. Rnfovtinol.* 6:1642). For additional examples of tissue-specific promoters, see U.S. Patent Nos. 5,834,306 and 5,416,027, and references cited therein.

In addition to a promoter, the genetic construct may also contain other genetic control elements, such as enhancers, repressible sequences, and silencers, which may be used to regulate replication of the vector in the target cell. The only requirement is that the genetic element be activated, derepressed, enhanced, or otherwise genetically regulated by factors in the host cell and, with respect to methods of treatment, not in the non-target cell.

An "element," when used in the context of nucleic acid constructs, refers to a region of the construct or a nucleic acid fragment having a defined function.

For example, an enhancer element, as used herein, is a region of DNA that, when associated with inserted nucleic acid molecule, operably linked to a promoter, enhances the transcription of that gene.

The term "enhancer" is used according to its art-recognized meaning. It is intended to mean a sequence found in eukaryotes which can increase transcription from a gene when located (in either orientation) up to several kilobases from the gene being studied. These sequences usually act as enhancers when on the 5' side (upstream) of the gene in question. However, some enhancers are active when placed on the 3' side (downstream) of the gene. In some cases, enhancer elements can activate transcription from a gene with no (known) promoter.

Preferred enhancers include the DF3 breast cancer-specific enhancer and enhancers from viruses and the steroid receptor family. Other preferred transcriptional regulatory sequences include NF1, SP1, AP1, and FOS/JUN.

Any of a variety of methods known to those skilled in the art may be used to introduce transfection vectors of the present invention into selected target tissue cells. Such methods include, for example, viral-mediated gene transfer using retroviruses, adeno-associated virus (AAV), herpes virus, vaccinia virus, or RNA viruses (*e.g.*, Grunhaus and Horowitz, *Semin. Virol.* 3:237-252 (1992); Herz and Gerard, *Proc. Nat. Acad. Sci. USA* 90:2812-2816 (1993); and Rosenfeld *et al.*, *Cell* 68:143-155 (1992)); liposome-mediated gene transfer (Morishita *et al.*, *J. Clin. Invest.* 91:2580 (1993); Felgner *et al.*, U.S. Patent Nos. 5,703,055 (1997) and 5,858,784 (1999)); injection of naked DNA directly into a target tissue (*e.g.*, Felgner *et al.*, U.S. Patent No. 5,589,466 (1996); Wolff *et al.*, U.S. Patent No. 5,693,622 (1997)); and receptor-mediated gene transfer (Wu and Wu, *Biochemistry* 27:887-892 (1988); Wagner *et al.*, *PNAS USA* 87:3410-3414 (1990); Curiel *et al.*, U.S. Patent 5,547,932 (1996); and Beug *et al.*, U.S. Patent No. 5,354,844 (1994)).

-18-

In any of these methods, where a vector may be targeted to selectively transfect a specific population of cells, it will be understood that in addition to local administration (such as may be achieved by injection into the target tissue), the vector may be administered systemically (e.g., intravenously) in a biologically-compatible solution or pharmaceutically acceptable delivery vehicle. Vector constructs administered in this way may selectively infect the target tissue. According to the present invention, the presence of a target tissue-specific promoter on the construct provides an independent means of restricting expression of the therapeutic gene.

Nucleic acid molecules encoding peptides which block antiproliferative compounds can also be useful in conjunction with chemotherapeutic agents in the treatment of skin cancer; many chemotherapeutic agents are effective only against dividing cells, and the blocking peptides can have the effect of inducing division of otherwise dormant cells, rendering them vulnerable to the chemotherapy. Nucleic acids encoding blocking peptides can also be useful in promoting growth of new cells, e.g., skin cells, in topical skin creams. Differentiation-inducing peptides can be used as immunostimulants, by inducing maturation of monocytes and lymphocytes bearing PTH receptors, while blocking peptides can be used to inhibit lymphocyte maturation, and thus can be used to treat conditions, e.g., autoimmune diseases such as juvenile diabetes, rheumatoid arthritis, and allograft rejection, where mature lymphocytes are a causative agent.

The nucleic acid molecules of the invention can be admixed with a pharmacologically inert topical carrier such as one comprising a gel, an ointment or a cream, including such carriers as water, glycerol, alcohol, propylene glycol, fatty alcohol, triglycerides, fatty acid ester or mineral oils. Other possible carriers are liquid petrolatum, isopropylpalmitate, polyethylene glycol ethanol 95%, polyoxyethylene monolaurate 5% in water, sodium lauryl sulfate 5% in water, and the like. Materials such as antioxidants, humectants, viscosity stabilizers and the like may be added, if necessary. Nucleic acid molecules can be incorporated into liposomes using methods outlined in U.S. Pat. 5,260,065.

The nucleic acid molecules can be incorporated into a collagenous biocompatible matrix similar to the methods utilized in Fang *et al.*, *Proc. Nat. Acad. Sci. U.S.A.* 93:5753 (1996) and U.S. Pat. 5,962,427. The types of matrices that may be used in the practice of the invention is virtually limitless and may include both biological and synthetic matrices. The matrices may be biodegradable or non-biodegradable. The matrices may take the form of sponges, implants, tubes, telfa pads, band-aids, bandages, pads, lyophilized components, gels, patches, powders or nanoparticles. Particular examples of such matrices include porous or collagenous materials (*e.g.* type II collagen), hydroxyapatite, bioglass, aluminates, bioceramic materials, purified proteins or extracellular matrix compositions as well as metals such as titanium.

The nucleic acid molecules can be provided in the form of pharmaceutically acceptable salts. Examples of preferred salts are those of therapeutically acceptable organic acids, *e.g.*, acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, salicylic, methanesulfonic, toluenesulfonic, or pamoic acid, as well as polymeric acids such as tannic acid or carboxymethyl cellulose, and salts with inorganic acids such as hydrohalic acids, *e.g.*, hydrochloric acid, sulfuric acid, or phosphoric acid.

Dosage will be dependent upon the age, health, and weight of the recipient; kind of concurrent treatment, if any; frequency of treatment; and the nature of the effect desired. Generally, daily dosage may be 0.001 to 500 $\mu\text{g}/\text{kg}$. The topical dosage may be from 0.01 to 100 $\mu\text{g}/\text{cm}^2$. The liposomal gel, ointment or cream formulations may be applied by one or more applications per day.

The invention also relates to compositions comprising a nucleic acid molecule of the invention, an active vitamin D compound and a pharmaceutical carrier, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when

- 20 -

expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair growth. A large number of active vitamin D compounds are known which can be used in the practice of the present invention. See U.S. Patent Nos. 5,457,217, 5,414,098, 5,384,313, 5,373,004, 5,371,249, 5,430,196, 5,260,290, 5,393,749, 5,395,830, 5,250,523, 5,247,104, 5,397,775, 5,194,431, 5,281,731, 5,254,538, 5,232,836, 5,185,150, 5,321,018, 5,086,191, 5,036,061, 5,030,772, 5,246,925, 4,973,584, 5,354,744, 4,927,815, 4,857,518, 4,851,401, 4,851,400, 4,847,012, 4,755,329, 4,940,700, 4,619,920, 4,594,192, 4,588,716, 4,564,474, 4,552,698, 4,588,528, 4,719,204, 4,719,205, 4,689,180, 4,505,906, 4,769,181, 4,502,991, 4,481,198, 4,448,726, 4,448,721, 4,428,946, 4,411,833, 4,367,177, 4,336,193, 4,360,472, 4,360,471, 4,307,231, 4,307,025, 4,358,406, 4,305,880, 4,279,826, and 4,248,791. A preferred active vitamin D compound is calcipotriene. In this embodiment, any conventional liposome may be used including the liposomes described in U.S. Pat. Nos. 4,235,871, 4,241,046, 4,247,411, 4,356,167, 4,377,567, 4,544,545, 4,551,288, 4,610,868, 4,731,210, 4,744,989, 4,772,471, 4,897,308, 4,917,951, 5,021,200, 5,032,457, and 5,260,065.

The invention relates as well to a method of inhibiting proliferation or enhancing differentiation of a skin or hair cell of a mammal, comprising administering to the mammal in need thereof a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule of the invention and an active vitamin D compound, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth. In this embodiment, the nucleic acid molecule encoding the peptide

and the active vitamin D compound may be administered as part of single or separate pharmaceutical compositions. Either one or both of the nucleic acid molecules and active vitamin D compound may be administered topically or parenterally. In a preferred embodiment, the nucleic acid molecule is administered first followed by the active vitamin D compound.

The following examples are illustrative, but not limiting, of the method and compositions of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.

Example 1

Mini-gene construction

PTHrP gene: PTHrP gene expresses three isoform peptides: PTHrP 1-139, PTHrP1-141 and PTHrP 1-173. The gene splicing happens between exon 4 to exon 6. The 5'-flanking regions share common nucleotide sequences, including precursor peptide. PTHrP mini-genes were made based on the nucleotide sequences of the human PTHrP/PLP gene, (Yasuda *et al. J. Biol. Chem.* 264:7720 (1989)) by using the PCR technique. The interested gene fragments were constructed into pCR3.1eukaryotic expression vector. The forward primer for PTHrP (1-139), PTHrP (1-141), PTHrP (1-173) and PTHrP (1-34) is 5'-AGCGGAGACGATGCAGCGGAGA-3' (SEQ ID NO: 26), reverse primer for PTHrP (1-139) is 5'-AAGGGAGGCAGCTGAGACG-3' (SEQ ID NO: 27), for PTHrP (1-141) is 5'-GTCCTTGGAAGGTCTCTGCTG-3' (SEQ ID NO: 28), for PTHrP (1-173) is 5'-TTCTAGTGCCACTGCCCATTTG-3' (SEQ ID NO:29) and for PTHrP (1-34) is 5'-CTACTAAGCTGTGTGGATTCTGCGAT-3' (SEQ ID NO:

- 22 -

30). PCR was performed at 94°C for 3 min initial denaturing, then followed by denaturing for 30 seconds at 94°C, annealing for 30 seconds at 60°C and extension for 1 min at 72°C, total 30 cycles, additional extension for 10 min at 72°C.

5

Adenovirus construction of PTHrP

The corresponding mature and fragment forms of PTH or PTHrP cDNAs (FIG. 2) can be subcloned into the adenovirus expression vector, pACCMV.pLpA (FIG. 3). Once the PTH and PTHrP inserts are subcloned and purified they are co-transfected with pJM17 in 293 cells, which contains essential elements of the adenovirus genome to replicate and produce recombinant virions. The virions isolated for the co-transfected 293 cells are infectious but don't have the capacity to replicated in other cell types except 293 cells with the pJM17 vector. The purified pACCMV.pLpA. PTHrP virion particles can then be used for gene transfer of the various PTHrPs cDNAs driven by the CMV promoter in culture and animals (Tomas C. Berker, *et al.* Methods of Cell Biology, Use of Recombinant Adenovirus for Metabolic Engineering of Mammalian Cells, Vol. 43, Chp 8; pg. 161-187, Academic Press Inc., San Diego, CA., USA. 1994).

20

Transfection

Keratinocytes were maintained in MCDB-153 medium. Cells in 24 well dishes at 50%-60% confluence were transfected with 1 µg/ml of PTHrP cDNA which was constructed into pCR3.1 vector (INVITROGEN, San Diego, CA., USA), empty vector as a control. For each transfection, 0.5 micrograms of DNA and 3 microliters of LIPOFECTAMINE were diluted in 50 microliters of serum free media, respectively, and then combined for a DNA/ Liposome

25

- 23 -

complexing incubation for 15 minute at room temperature. DNA/ Liposome complex was then incubated on the cells for 3 hours. After 3 hour of transfection, fresh media was added and cells were incubated for 21 hours.

5 ***³H - Thymidine Incorporation***

³H-thymidine incorporation into DNA was used as an index of cell proliferation as described previously (Smith E.L. *et al. J. Invert. Dermatology* 86:709 (1986), Holick *et al. Proc. Nat. Acad. Sci. U.S.A.* 91:8014 (1994)). Twenty-four hours post transfection the medium was replaced with 0.5 ml of
10 fresh basal medium containing [methyl-³H]thymidine (New England Nuclear, Boston, MA) and incubated for 3 h at 37° C. ³H-Thymidine incorporation into DNA was stopped by placing the 24-well plates on ice. Unincorporated ³H-thymidine was then removed and the cells were washed three times with ice-cold phosphate-buffered saline. DNA labeled with ³H-thymidine and other
15 macromolecules were first precipitated with ice-cold 5% perchloric acid for 20 min and then extracted with 0.5 ml of 5% perchloric acid at 70 °C for 20 min. The radioactivity in the extracts was determined by a liquid scintillation counter. The results were expressed as percent of control.

Experiments have shown that when normal cultured human
20 keratinocytes are transfected with plasmids containing PTHrP (1-141) or PTHrP (1-173) an unexpected enhancement of cell growth is seen, as measured by ³H-thymidine incorporation into epidermal DNA (FIG. 1). These results may be due to proteolysis of the full length peptide.

Having now fully described this invention, it will be understood by
25 those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated by

reference herein in their entirety.

What Is Claimed Is:

1. A method of inhibiting proliferation or enhancing differentiation of a mammalian skin or hair cell, said method comprising administering to the mammalian skin or hair cell in need of inhibited proliferation or enhanced differentiation with a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth.

2. The method of claim 1, wherein said nucleic acid molecule is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

3. The method of claim 2, wherein said carrier is a liposome.

4. The method of claim 1, wherein said nucleic acid molecule is contained within a porous biocompatible matrix.

5. The method of claim 1, wherein said peptide encoded by the nucleic acid molecule is PTH (1-34) (SEQ ID NO: 18), PTHrP (1-34) (SEQ ID NO: 31), PTH (1-84) (SEQ ID NO: 15), PTHrP (1-141) (SEQ ID NO: 32), PTHrP (1-139) (SEQ ID NO: 33) or PTHrP (1-173) (SEQ ID NO: 34).

- 26 -

6. The method of claim 1, wherein said nucleic acid molecule is one of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, or a fragment thereof.

5 7. The method of claim 1, wherein said nucleic acid molecule is administered topically to the mammalian skin or hair cells.

8. The method of claim 1, wherein said method is a method of inhibiting a hyperproliferative skin disorder.

9. The method of claim 8, wherein said hyperproliferative skin disorder is psoriasis, ichthyosis, eczema, acne, actinic keratosis, or skin cancer.

10 10. The method of claim 1, wherein said method is a method of inhibiting hair growth or preventing hair regrowth.

11. The method of claim 1, wherein said peptide encoded by the nucleic acid molecule has at least 75% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP.

15 12. The method of claim 1, further comprising administering to the mammalian hair or skin cell an effective amount of an active vitamin D compound.

13. The method of claim 12, wherein said active vitamin D compound is calcipotriene.

20 14. The method of claim 12, wherein said active vitamin D compound is 1,25-dihydroxyvitamin D₃.

- 27 -

15. The method of claim 12, wherein said active vitamin D compound is 19-nor-1,25-dihydroxyvitamin D₂.

16. The method of claim 12, wherein said active vitamin D compound is 19-nor-1,25-dihydroxyvitamin D₃.

5 17. The method of claim 12, wherein said nucleic acid molecule and active vitamin D compound are administered topically or parenterally.

18. The method of claim 1, wherein said nucleic acid molecule is operably linked to a promoter.

10 19. The method of claim 1, wherein said nucleic acid molecule is contained by a plasmid.

20. The method of claim 1, wherein said nucleic acid molecule is contained by a viral vector.

15 21. A method of inhibiting proliferation or enhancing differentiation of a skin or hair cell of a mammal, said method comprising administering to the mammal in need thereof a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule and an active vitamin D compound, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when
20 expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth.

- 28 -

22. The method of claim 21, wherein said nucleic acid molecule and said active vitamin D compound are administered as part of a single pharmaceutical composition.

23. The method of claim 21, wherein said nucleic acid molecule and said active vitamin D compound are administered as part of separate pharmaceutical compositions.

24. The method of claim 21, wherein said nucleic acid molecule is administered parentally.

25. The method of claim 21, wherein said active vitamin D compound is administered topically.

26. The method of claim 21, wherein said active vitamin D compound is administered orally.

27. The method of claim 21, wherein said nucleic acid molecule is encapsulated within a liposome.

28. The method of claim 21, wherein said nucleic acid molecule is contained within a porous biocompatible matrix.

29. A method of inducing proliferation of a mammalian skin or hair cell, said method comprising administering to the mammalian skin or hair cell in need of proliferation with a proliferation-inducing amount of a nucleic acid molecule, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro

- 29 -

of cultured human keratinocytes by PTH (1-34), 1,25(OH)₂D₃ or PTHrP (1-34), or *in vivo* in mouse skin by stimulating skin cell proliferation or accelerating hair cycle progression or stimulating hair cell growth.

5 30. The method of claim 29, wherein said nucleic acid molecule is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

31. The method of claim 30, wherein said carrier is a liposome.

32. The method of claim 29, wherein said nucleic acid molecule is contained within a porous biocompatible matrix.

10 33. The method of claim 29, which is a method of stimulating skin cell growth, rejuvenating aged skin, preventing skin wrinkles, treating skin wrinkles, enhancing wound healing, stimulating hair growth, maintaining hair growth, treating or preventing female or male pattern baldness, or treating chemotherapy induced alopecia.

15 34. The method of claim 29, which is a method of stimulating epidermal cell growth or hair follicle cell growth.

20 35. The method of claim 29, wherein said peptide encoded by the nucleic acid molecule is PTH (7-34) (SEQ ID NO: 35), PTHrP (7-34) (SEQ ID NO: 36), PTH (5-36) (SEQ ID NO: 37), PTHrP (5-36) (SEQ ID NO: 38), PTH (5-34) (SEQ ID NO: 39), PTHrP (5-34) (SEQ ID NO: 40), PTH (7-84) (SEQ ID NO: 12), PTHrP (7-139) (SEQ ID NO: 41), PTHrP (4-141) (SEQ ID NO: 42), or PTHrP (7-173) (SEQ ID NO: 43)

- 30 -

36. The method of claim 1, wherein said nucleic acid molecule is one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, or a fragment thereof.

5 37. A composition comprising a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule encapsulated within a liposome, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of
10 cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth.

38. The method of claim 37, wherein said nucleic acid molecule is contained within a porous biocompatible matrix.

15 39. A composition comprising a proliferation-inducing amount of a nucleic acid molecule encapsulated within a liposome, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro of cultured human
20 keratinocytes by PTH (1-34), 1,25(OH)₂D₃ or PTHrP (1-34), or *in vivo* in mouse skin by stimulating skin cell proliferation or accelerating hair cycle progression or stimulating hair cell growth.

25 40. A composition comprising a proliferation-inhibiting or differentiation-enhancing amount of a nucleic acid molecule and an active vitamin D compound, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity

- 31 -

with the 34 amino acid N-terminal region of hPTH or hPTHrP, and, when expressed, is capable of inhibiting proliferation or enhancing differentiation *in vitro* of cultured human keratinocytes, or *in vivo* in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth.

- 5 41. The composition of claim 40, wherein at least one of said nucleic acid molecules or active vitamin D compound is encapsulated by liposomes.

1/12




FIG.1

2/12

PTHrP cDNA STRUCTURE




FIG.2A





FIG.2B



(Met-(-1AA) PRECURSOR PEPTIDE)

FIG.2C

3/12




FIG.3

4/12

SEQ ID NO: 1 - Human Parathyroid Hormone Coding Sequence (hPTH)
TCTGTGAGTGAAATACAGCTTATGCATAACCTGGGAAAACATCTGAACTC
GATGGAGAGAGTAGAATGGCTGCGTAAGAAGCTGCAGGATGTGCACAATT
TTGTTGCCCTTGGAGCTCCTCTAGCTCCCAGAGATGCTGGTTCCCAGAGG
CCCCGAAAAAAGGAAGACAATGTCTTGGTTGAGAGCCATGAAAAAGTCT
TGGAGAGGCAGACAAAGCTGATGTGAATGTATTAATAAGCTAAATCCC
AGTGA

FIG.4

SEQ ID NO: 2 - Bovine Parathyroid Hormone Coding Sequence (bPTH)
GCTGTGAGTGAAATACAGTTTATGCATAACCTGGGCAAACATCTGAGCTC
CATGGAAAGAGTGGAATGGCTGCGGAAAAAGCTACAGGATGTGCACAAC
TTGTTGCCCTTGGAGCTTCTATAGCTTACAGAGATGGTAGTTCCCAGAGA
CCTCGAAAAAAGGAAGACAATGTCCTGGTTGAGAGCCATCAGAAAAGTCT
TGGAGAAGCAGACAAAGCTGATGTGGATGTATTAATTAAAGCTAAACCCC
AG

FIG.5

SEQ ID NO: 3 - Human Parathyroid Hormone Related Protein Coding
Sequence(PTHrP)
GCTGTGTCTGAACATCAGCTCCTCCATGACAAGGGGAAGTCCATCCAAGA
TTTACGGCGACGATTCTTCCTTCACCATCTGATCGCAGAAATCCACACAG
CTGAAATCAGAGCTACCTCGGAGGTGTCCCCTAACTCCAAGCCCTCTCCC
AACACAAAGAACCACCCCGTCCGATTTGGGTCTGATGATGAGGGCAGATA
CCTAACTCAGGAACTAACAAGGTGGAGACGTACAAAGAGCAGCCGCTCA
AGACACCTGGGAAGAAAAAGAAAGGCAAGCCCGGGAACGCAAGGAGCAG
GAAAAGAAAAAACGGCGAACTCGCTCTGCCTGGTTAGACTCTGGAGTGAC
TGGGAGTGGGCTAGAAGGGGACCACCTGTCTGACACCTCCACAACGTCGC
TGGAGCTCGATTACGGAGGCATTGA

FIG.6

SEQ ID NO: 4 - Rat Parathyroid Hormone Coding Sequence (rPTH)
GCTGTCAGTGAAATACAGCTTATGCACAACCTGGGCAAACACCTGGCCTC
TGTGGAGAGGATGCAATGGCTGAGAAAAAAGCTGCAAGATGTACACAATT
TTGTTAGTCTTGGAGTCCAAATGGCTGCCAGAGAAGGCAGTTACCAGAGG
CCCACCAAGAAGGAGGAAAATGTCCTTGTGATGGCAATTCAAAAAGTCT
TGGCGAGGGGGACAAAGCTGATGTGGATGTATTAGTTAAGGCTAAATCTC
AGTAA

FIG.7

SUBSTITUTE SHEET (RULE 26)

5/12

SEQ ID NO:5 - hPTH (1-31)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDV

FIG.8

SEQ ID NO:6 - PTHrP - (1-40)
H₂N-Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-
Leu-Arg-Arg-Arg-Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-
Glu-Ile-Arg-Ala-Thr-Ser-OH

FIG.9

SEQ ID NO:7 - PTH, Bovine (bPTH) (84 amino acids)
H₂N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-
Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-
Ala-Leu-Gly-Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-Arg-Lys-
Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-Lys-Ser-Leu-Gly-Glu-Ala-Asp-
Lys-Ala-Asp-Val-Asp-Val-Leu-Ile-Lys-Ala-Lys-Pro-Gln-OH

FIG10

SEQ ID NO:8 - [Tyr⁶³] -hPTH (63-84)
H₂N-Tyr-Glu-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-
Lys-Ala-Lys-Ser-Gln-OH

FIG.11

SEQ ID NO:9 - hPTH (64-84)
H₂N-Glu-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-
Ala-Lys-Ser-Gln-OH

FIG.12

SEQ ID NO:10 - [Tyr⁶⁹] -hPTH (69-84)
H₂N-Tyr-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-OH

FIG.13

6/12

SEQ ID NO:11 - hPTH (70-84)

H₂N-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-OH

FIG.14

SEQ ID NO:12 - hPTH (7-84)

H₂N-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg-Asp-Ala-Gly-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Glu-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-OH

FIG.15

SEQ ID NO:13 - hPTHrP (1-31)-

AVSEHQLLDKKGKSIQDLRRRFFLHHLIAEIH

FIG.16

SEQ ID NO:14 - hPTH (1-34)

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF

FIG.17

SEQ ID NO:15 - hPTH (84 amino acids)

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg-Asp-Ala-Gly-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Glu-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-OH (Kimura, T. et al, (1983) BBRC 114493; Fairwell, T. et al, (1983) Biochemistry 222691)

FIG.18

7/12

SEQ ID NO:16 - Rat PTH (rPTH) (84 amino acids)

H₂N-Ala-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ala-Ser-
Val-Glu-Arg-Met-Gln-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-
Val-Ser-Leu-Gly-Val-Gln-Met-Ala-Ala-Arg-Glu-Gly-Ser-Tyr-Gln-Arg-Pro-
Thr-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Asp-Gly-Asn-Ser-Lys-Ser-Leu-Gly-
Glu-Gly-Asp-Lys-Ala-Asp-Val-Asp-Val-Leu-Val-Lys-Ala-Lys-Ser-Gln-
OH (Heinrich, G. et al, (1984) J. Biol. Chem. 259:3320)

FIG.19

SEQ ID NO:17 - bPTH (1-34)

H₂N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-
Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH
(Tregear, G. W. et al, (1977) Biochemistry 16:2817)

FIG.20

SEQ ID NO:18 - hPTH (1-34)

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-
Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH
(Takei, T. et al, (1979) Peptide Chemistry)

FIG.21

SEQ ID NO:19 - [Tyr¹] -hPTH (1-34)

H₂N-Tyr-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-
Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH

FIG.22

SEQ ID NO:20 - hPTH (1-38)

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-
Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-
Val-Ala-Leu-Gly-OH (Heech, R. D. et al, (1984) Horm. Metab. Res. 16:556)

FIG.23

SEQ ID NO:21 - bPTH (3-34)

H₂N-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met-Glu-
Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH (Lowrik,
C. et al, (1985) Cell Calcium 6:311)

FIG.24

SUBSTITUTE SHEET (RULE 26)

8/12

SEQ ID NO:22 - hPTH (13-34)

H₂N-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-
Gln-Asp-Val-His-Asn-Phe-OH

FIG.25

SEQ ID NO:23 - [Tyr²⁷]-hPTH (27-28)

H₂N-Tyr-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-
Pro-Arg-Asp-Ala-Gly-Ser-OH

FIG.26

SEQ ID NO:24 - hPTH (28-48)

H₂N-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg-
Asp-Ala-Gly-Ser-OH Rosenblatt, M. et al, (1977) Biochemistry 16:2811)

FIG.27

SEQ ID NO:25 - hPTH (53-84)

H₂N-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Glu-Lys-Ser-Leu-Gly-Glu-
Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln-OH
(Rosenblatt, M. et al, (1978) Endocrinology 103:976)

FIG.28

SEQ ID NO: 26 - Oligo -

5'-AGCGGAGACGATGCAGCGGAGA-3'

FIG.29

SEQ ID NO: 27 - Oligo -

5'-AAGGGAGGCAGCTGAGACG-3'

FIG.30

9/12

SEQ ID NO: 28 - Oligo -
5'-GTCCTTGAAGGTCTCTGCTG-3'

FIG.31

SEQ ID NO: 29 - Oligo -
5'-TTCTAGTGCCACTGCCCAT TG-3'

FIG.32

SEQ ID NO: 30 - Oligo -
5'-CTACTAAGCTGTGTGGATTCTGCGAT-3'

FIG.33

SEQ ID NO: 31 - hPTHrP- (1-34) -
AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHAE

FIG.34

SEQ ID NO: 32 - hPTHrP (1-141) -
AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHAEIRATSEVSPNSKPSNTKNHPVRFSGSDDEGR
YLTQETNKVETYKEQPLKTPGKKKKGKPGKRKEQEKKRRTRSAWLDSGVTGSGLEGD
HLSDTSTTSLELDSRRH

FIG.35

SEQ ID NO: 33 - hPTHrP (1-139) -
AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHAEIRATSEVSPNSKPSNTKNHPVRFSGSDDEGR
YLTQETNKVETYKEQPLKTPGKKKKGKPGKRKEQEKKRRTRSAWLDSGVTGSGLEGD
HLSDTSTTSLELDSR

FIG.36

10/12

SEQ ID NO: 34 - hPTHrP (1-173) -
Met-Gln-Arg-Arg-Leu-Val-Gln-Gln-Trp-Ser-Val-Ala-Val-Phe-Leu
Leu-Ser-Tyr-Ala-Val-Pro-Ser-Cys-Gly-Arg-Ser-Val-Glu-Gly-Leu
Ser-Arg-Arg-Leu-Lys-Arg-Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His
Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Phe-Phe-Leu
His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-Glu-Ile-Arg-Ala-Thr
Ser-Glu-Val-Ser-Pro-Asn-Ser-Lys-Pro-Ser-Pro-Asn-Thr-Lys-Asn
His-Pro-Val-Arg-Phe-Gly-Ser-Asp-Asp-Glu-Gly-Arg-Tyr-Leu-Thr
Gln-Glu-Thr-Asn-Lys-Val-Glu-Thr-Tyr-Lys-Glu-Gln-Pro-Leu-Lys
Thr-Pro-Gly-Lys-Lys-Lys-Lys-Gly-Lys-Pro-Gly-Lys-Arg-Lys-Glu
Gln-Glu-Lys-Lys-Lys-Arg-Arg-Thr-Arg-Ser-Ala-Trp-Leu-Asp-Ser
Gly-Val-Thr-Gly-Ser-Gly-Leu-Glu-Gly-Asp-His-Leu-Ser-Asp-Thr
Ser-Thr-Thr-Ser-Leu-Glu-Leu-Asp-Ser-Arg-Thr-Ala-Leu-Leu-Trp
Gly-Leu-Lys-Lys-Lys-Lys-Glu-Asn-Asn-Arg-Arg-Thr-His-His-Met
Gln-Leu-Met-Ile-Ser-Leu-Phe-Lys-Ser-Pro-Leu-Leu-Leu-Leu-End

FIG.37

SEQ ID NO: 35 - hPTH (7-34) -
LMHNLGKHLNSMERVEWLRKKLQDVHNF

FIG.38

SEQ ID NO: 36 - hPTHrP (7-34) -
LLHDKGKSIQDLRRRFFLHHLIAEIHTAE

FIG.39

SEQ ID NO: 37 - hPTH (5-36) -
IQLMHNLGKHLNSMERVEWLRKKLQDVHNFVA

FIG.40

SEQ ID NO: 38 - hPTHrP (5-36)
H₂N-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-
Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-Glu-Ile-OH

FIG.41

11/12

SEQ ID NO: 39 - hPTH (5-34)

H₂N-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-
Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH

FIG.42

SEQ ID NO: 40 - hPTHrP (5-34)

H₂N-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-
Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-OH

FIG.43

SEQ ID NO: 41 - hPTHrP (7-139) -

LLHDKGKSIQDLRRRFFLHHLIAEIHAEIRATSEVSPNSKPSNTKNHPVRFGSDDEGR
YLTQETNKVETYKEQPLKTPGKKKKGKPGKRKEQEKKKRRTRSAWLDSGVTGSGLEGD
HLSDTSTTSLELDSR

FIG.44

SEQ ID NO: 42 - hPTHrP (7-141) -

LLHDKGKSIQDLRRRFFLHHLIAEIHAEIRATSEVSPNSKPSNTKNHPVRFGSDDEGR
YLTQETNKVETYKEQPLKTPGKKKKGKPGKRKEQEKKKRRTRSAWLDSGVTGSGLEGD
HLSDTSTTSLELDSRRH

FIG.45

12/12

SEQ ID NO: 43 - hPTHrP (7-173) -
Gln-Gln-Trp-Ser-Val-Ala-Val-Phe-Leu

Leu-Ser-Tyr-Ala-Val-Pro-Ser-Cys-Gly-Arg-Ser-Val-Glu-Gly-Leu
Ser-Arg-Arg-Leu-Lys-Arg-Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His
↓
Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Phe-Phe-Leu
His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-Glu-Ile-Arg-Ala-Thr
Ser-Glu-Val-Ser-Pro-Asn-Ser-Lys-Pro-Ser-Pro-Asn-Thr-Lys-Asn
His-Pro-Val-Arg-Phe-Gly-Ser-Asp-Asp-Glu-Gly-Arg-Tyr-Leu-Thr
Gln-Glu-Thr-Asn-Lys-Val-Glu-Thr-Tyr-Lys-Glu-Gln-Pro-Leu-Lys
Thr-Pro-Gly-Lys-Lys-Lys-Lys-Gly-Lys-Pro-Gly-Lys-Arg-Lys-Glu
Gln-Glu-Lys-Lys-Lys-Arg-Arg-Thr-Arg-Ser-Ala-Trp-Leu-Asp-Ser
Gly-Val-Thr-Gly-Ser-Gly-Leu-Glu-Gly-Asp-His-Leu-Ser-Asp-Thr
Ser-Thr-Thr-Ser-Leu-Glu-Leu-Asp-Ser-Arg-Thr-Ala-Leu-Leu-Trp
Gly-Leu-Lys-Lys-Lys-Lys-Glu-Asn-Asn-Arg-Arg-Thr-His-His-Met
Gln-Leu-Met-Ile-Ser-Leu-Phe-Lys-Ser-Pro-Leu-Leu-Leu-Leu-End

FIG.46

SEQ ID NO: 44 - hPTH (1-44)
H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-
Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-
Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg-OH (Kimura T. et al, (1981)
Biopolymers 20:1823)

FIG.47

-1-

SEQUENCE LISTING

<110> Holick, Michael F.

<120> Regulation of Cell Proliferation And Differentiation Using Topically Applied Nucleic Acid Molecules

<130> 1539.032PC00

<140>

<141>

<150> US 60/238,134

<151> 2000-10-06

<160> 44

<170> PatentIn version 3.0

<210> 1

<211> 255

<212> DNA

<213> Human Parathyroid Hormone Coding Sequence (hPTH)

<400> 1

tctgtgagtg aaatacagct tatgcataac ctgggaaaac atctgaactc gatggagaga 60

gtagaatggc tgcgtaagaa gctgcaggat gtgcacaatt ttgttgccct tggagctcct 120

ctagctccca gagatgctgg ttcccagagg ccccgaaaaa aggaagacaa tgtcttggtt 180

gagagccatg aaaaaagtct tggagaggca gacaaagctg atgtgaatgt attaactaaa 240

gctaaatccc agtga 255

<210> 2

<211> 252

<212> DNA

<213> Bovine Parathyroid Hormone Coding Sequence (bPTH)

<400> 2

gctgtgagtg aaatacagtt tatgcataac ctgggcaaac atctgagctc catggaaaga 60

gtggaatggc tgcggaaaaa gctacaggat gtgcacaact ttgttgccct tggagcttct 120

atagcttaca gagatggtag ttcccagaga cctcgaaaaa aggaagacaa tgccttggtt 180

gagagccatc agaaaagtct tggagaagca gacaaagctg atgtggatgt attaattaaa 240

gctaaacccc ag 252

<210> 3

<211> 426

<212> DNA

<213> Human Parathyroid Hormone Related Protein Coding Sequence (PTHrP)

<400> 3

gctgtgtctg aacatcagct cctccatgac aagggaagt ccatccaaga ttacggcgca 60

-2-

```

cgattcttcc ttcaccatct gatcgagaaa atccacacag ctgaaatcag agctacctcg      120
gagggtgtccc ctaactccaa gccctctccc aacacaaaaga accaccccggt ccgatttggg      180
tctgatgatg agggcagata cctaactcag gaaactaaca aggtggagac gtacaaagag      240
cagccgctca agacacctgg gaagaaaaag aaaggcaagc ccgggaaacg caaggagcag      300
gaaaagaaaa aacggcgaac tcgctctgcc tggtagact ctggagtgc tgggagtggg      360
ctagaagggg accacctgtc tgacacctcc acaacgtcgc tggagctcga ttcacggagg      420
cattga                                          426

```

<210> 4
 <211> 255
 <212> DNA
 <213> Rat Parathyroid Hormone Coding Sequence (rPTH)

```

<400> 4
gctgtcagtg aaatacagct tatgcacaac ctgggcaaac acctggcctc tgtggagagg      60
atgcaatggc tgagaaaaaa gctgcaagat gtacacaatt ttgtagtct tggagtccaa      120
atggctgcca gagaaggcag ttaccagagg cccaccaaga aggaggaaaa tgccttgtt      180
gatggcaatt caaaaagtct tggcgagggg gacaaagctg atgtggatgt attagttaag      240
gctaaatctc agtaa                                          255

```

<210> 5
 <211> 30
 <212> PRT
 <213> hPTH (1-31)

```

<400> 5
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1           5           10           15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Leu Gln Asp Val
          20          25          30

```

<210> 6
 <211> 40
 <212> PRT
 <213> PTHrP - (1-40)

```

<400> 6
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1           5           10           15
Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
          20          25          30
Thr Ala Glu Ile Arg Ala Thr Ser
          35          40

```

<210> 7
 <211> 84

-3-

<212> PRT
 <213> bPTH

<400> 7
 Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
 1 5 10 15
 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30
 Asn Phe Val Ala Leu Gly Ala Ser Ile Ala Tyr Arg Asp Gly Ser Ser
 35 40 45
 Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Gln
 50 55 60
 Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ile Lys
 65 70 75 80
 Ala Lys Pro Gln

<210> 8
 <211> 22
 <212> PRT
 <213> [Tyr⁶³] hPTH (63-84)

<400> 8
 Tyr Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu
 1 5 10 15
 Thr Lys Ala Lys Ser Gln
 20

<210> 9
 <211> 21
 <212> PRT
 <213> hPTH (64-84)

<400> 9
 Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr
 1 5 10 15
 Lys Ala Lys Ser Gln
 20

<210> 10
 <211> 16
 <212> PRT
 <213> [Tyr⁶⁹] hPTH (69-84)

<400> 10
 Tyr Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln
 1 5 10 15

<210> 11
 <211> 15
 <212> PRT
 <213> hPTH (70-84)

-4-

<400> 11
 Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln
 1 5 10 15

<210> 12
 <211> 78
 <212> PRT
 <213> hPTH (7-84)

<400> 12
 Leu Met His Asn Leu Gly Lys His Leu Asn Ser Met Glu Arg Val Glu
 1 5 10 15
 Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Phe Val Ala Leu Gly
 20 25 30
 Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gln Arg Pro Arg Lys Lys
 35 40 45
 Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala
 50 55 60
 Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln
 65 70 75

<210> 13
 <211> 32
 <212> PRT
 <213> hPTHrP (1-31)

<400> 13
 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
 1 5 10 15
 Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
 20 25 30

<210> 14
 <211> 34
 <212> PRT
 <213> hPTH (1-34)

<400> 14
 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
 1 5 10 15
 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30

Asn Phe

<210> 15
 <211> 84
 <212> PRT
 <213> hPTH

<400> 15
 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn

-5-

[illegible]

<210>	16
<211>	84
<212>	PRT
<213>	rPTH

```

<400>      16
Ala Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Ala
1              5              10              15
Ser Val Glu Arg Met Gln Trp Leu Arg Lys Lys Leu Gln Asp Val His
                20              25              30
Asn Phe Val Ser Leu Gly Val Gln Met Ala Ala Arg Glu Gly Ser Tyr
                35              40              45
Gln Arg Pro Thr Lys Lys Glu Asp Asn Val Leu Val Asp Gly Asn Ser
    50              55              60
Lys Ser Leu Gly Glu Gly Asp Lys Ala Asp Val Asp Val Leu Val Lys
65              70              75              80
Ala Lys Ser Gln

```

```
<210> 17
<211> 34
<212> PRT
<213> bPTH (1-34)
```

```

<400>      17
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1          5          10          15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
          20          25          30

```

Asn Phe

```
<210> 18
<211> 34
<212> PRT
<213> hPTH (1-34) .
```

<400> 18

-6-

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
 1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30

Asn Phe

<210> 19
 <211> 34
 <212> PRT
 <213> [Tyr¹] hPTH (1-34)

<400> 19
 Tyr Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
 1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30

Asn Phe

<210> 20
 <211> 38
 <212> PRT
 <213> hPTH (1-38)

<400> 20
 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
 1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30

Asn Phe Val Ala Leu Gly
 35

<210> 21
 <211> 32
 <212> PRT
 <213> bPTH (3-34) ..

<400> 21
 Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser Ser Met
 1 5 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Phe
 20 25 30

<210> 22
 <211> 22
 <212> PRT
 <213> hPTH (13-34)

<400> 22
 Lys His Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu
 1 5 10 15

-7-

Gln Asp Val His Asn Phe
20

<210> 23
<211> 22
<212> PRT
<213> [Tyr²⁷] hPTH (27-28)

<400> 23
Tyr Leu Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala
1 5 10 15

Pro Arg Asp Ala Gly Ser
20

<210> 24
<211> 21
<212> PRT
<213> hPTH (28-48)

<400> 24
Leu Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro
1 5 10 15

Arg Asp Ala Gly Ser
20

<210> 25
<211> 32
<212> PRT
<213> hPTH (53-84)

<400> 25
Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly
1 5 10 15

Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln
20 25 30

<210> 26
<211> 22
<212> DNA
<213> Oligonucleotide

<400> 26
agcggagacg atgcagcgga ga 22

<210> 27
<211> 19
<212> DNA
<213> Oligonucleotide

<400> 27
aagggaggca gctgagacg 19

<210> 28

-8-

<211> 21
 <212> DNA
 <213> Oligonucleotide

<400> 28
 gtccttggaagggtctctgct g 21

<210> 29
 <211> 21
 <212> DNA
 <213> Oligonucleotide

<400> 29
 ttctagtgcc actgcccatt g 21

<210> 30
 <211> 27
 <212> DNA
 <213> Oligonucleotide

<400> 30
 ctactaagct gtgtggattt ctgcgat 27

<210> 31
 <211> 35
 <212> PRT
 <213> hPTHrP (1-34)

<400> 31
 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
 1 5 10 15
 Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
 20 25 30
 Thr Ala Glu
 35

<210> 32
 <211> 141
 <212> PRT
 <213> hPTHrP (1-141)

<400> 32
 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
 1 5 10 15
 Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
 20 25 30
 Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser Lys Pro
 35 40 45
 Ser Pro Asn Thr Lys Asn His Pro Val Arg Phe Gly Ser Asp Asp Glu
 50 55 60
 Gly Arg Tyr Leu Thr Gln Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu
 65 70 75 80

-9-

Gln Pro Leu Lys Thr Pro Gly Lys Lys Lys Lys Gly Lys Pro Gly Lys
 85 90 95

Arg Lys Glu Gln Glu Lys Lys Lys Arg Arg Thr Arg Ser Ala Trp Leu
 100 105 110

Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp His Leu Ser Asp
 115 120 125

Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg Arg His
 130 135 140

<210> 33
 <211> 139
 <212> PRT
 <213> hPTHrP (1-139)

<400> 33
 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
 1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
 20 25 30

Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser Lys Pro
 35 40 45

Ser Pro Asn Thr Lys Asn His Pro Val Arg Phe Gly Ser Asp Asp Glu
 50 55 60

Gly Arg Tyr Leu Thr Gln Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu
 65 70 75 80

Gln Pro Leu Lys Thr Pro Gly Lys Lys Lys Lys Gly Lys Pro Gly Lys
 85 90 95

Arg Lys Glu Gln Glu Lys Lys Lys Arg Arg Thr Arg Ser Ala Trp Leu
 100 105 110

Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp His Leu Ser Asp
 115 120 125

Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg
 130 135

<210> 34
 <211> 209
 <212> PRT
 <213> hPTHrP (1-173)

<400> 34
 Met Gln Arg Arg Leu Val Gln Gln Trp Ser Val Ala Val Phe Leu Leu
 1 5 10 15

Ser Tyr Ala Val Pro Ser Cys Gly Arg Ser Val Glu Gly Leu Ser Arg
 20 25 30

Arg Leu Lys Arg Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly
 35 40 45

-10-

Lys Ser Ile Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile
 50 55 60
 Ala Glu Ile His Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro
 65 70 75 80
 Asn Ser Lys Pro Ser Pro Asn Thr Lys Asn His Pro Val Arg Phe Gly
 85 90 95
 Ser Asp Asp Glu Gly Arg Tyr Leu Thr Gln Glu Thr Asn Lys Val Glu
 100 105 110
 Thr Tyr Lys Glu Gln Pro Leu Lys Thr Pro Gly Lys Lys Lys Lys Gly
 115 120 125
 Lys Pro Gly Lys Arg Lys Glu Gln Glu Lys Lys Lys Arg Arg Thr Arg
 130 135 140
 Ser Ala Trp Leu Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp
 145 150 155 160
 His Leu Ser Asp Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg Thr
 165 170 175
 Ala Leu Leu Trp Gly Leu Lys Lys Lys Lys Glu Asn Asn Arg Arg Thr
 180 185 190
 His His Met Gln Leu Met Ile Ser Leu Phe Lys Ser Pro Leu Leu Leu
 195 200 205

Leu

<210> 35
 <211> 28
 <212> PRT
 <213> hPTH (7-34)

<400> 35
 Leu Met His Asn Leu Gly Lys His Leu Asn Ser Met Glu Arg Val Glu
 1 5 10 15
 Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Phe
 20 25

<210> 36
 <211> 29
 <212> PRT
 <213> hPTHrP (7-34)

<400> 36
 Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg Arg Arg Phe
 1 5 10 15
 Phe Leu His His Leu Ile Ala Glu Ile His Thr Ala Glu
 20 25

<210> 37
 <211> 32
 <212> PRT
 <213> hPTH (5-36)

-11-

<400> 37

Ile	Gln	Leu	Met	His	Asn	Leu	Gly	Lys	His	Leu	Asn	Ser	Met	Glu	Arg
1				5					10					15	

Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His	Asn	Phe	Val	Ala
			20					25					30		

<210> 38

<211> 32

<212> PRT

<213> hPTHrP (5-36)

<400> 38

His	Gln	Leu	Leu	His	Asp	Lys	Gly	Lys	Ser	Ile	Gln	Asp	Leu	Arg	Arg
1				5					10					15	

Arg	Phe	Phe	Leu	His	His	Leu	Ile	Ala	Glu	Ile	His	Thr	Ala	Glu	Ile
			20					25						30	

<210> 39

<211> 30

<212> PRT

<213> hPTH (5-34)

<400> 39

Ile	Gln	Leu	Met	His	Asn	Leu	Gly	Lys	His	Leu	Asn	Ser	Met	Glu	Arg
1				5					10					15	

Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His	Asn	Phe
			20					25					30

<210> 40

<211> 30

<212> PRT

<213> hPTHrP (5-34)

<400> 40

His	Gln	Leu	Leu	His	Asp	Lys	Gly	Lys	Ser	Ile	Gln	Asp	Leu	Arg	Arg
1				5					10					15	

Arg	Phe	Phe	Leu	His	His	Leu	Ile	Ala	Glu	Ile	His	Thr	Ala
			20					25					30

<210> 41

<211> 133

<212> PRT

<213> hPTHrP (7-139)

<400> 41

Leu	Leu	His	Asp	Lys	Gly	Lys	Ser	Ile	Gln	Asp	Leu	Arg	Arg	Arg	Phe
1				5					10					15	

Phe	Leu	His	His	Leu	Ile	Ala	Glu	Ile	His	Thr	Ala	Glu	Ile	Arg	Ala
				20				25						30	

Thr	Ser	Glu	Val	Ser	Pro	Asn	Ser	Lys	Pro	Ser	Pro	Asn	Thr	Lys	Asn
			35					40					45		

His	Pro	Val	Arg	Phe	Gly	Ser	Asp	Asp	Glu	Gly	Arg	Tyr	Leu	Thr	Gln
						55					60				

-12-

Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu Gln Pro Leu Lys Thr Pro
 65 70 75 80
 Gly Lys Lys Lys Lys Gly Lys Pro Gly Lys Arg Lys Glu Gln Glu Lys
 85 90 95
 Lys Lys Arg Arg Thr Arg Ser Ala Trp Leu Asp Ser Gly Val Thr Gly
 100 105 110
 Ser Gly Leu Glu Gly Asp His Leu Ser Asp Thr Ser Thr Thr Ser Leu
 115 120 125
 Glu Leu Asp Ser Arg
 130

<210> 42
 <211> 135
 <212> PRT
 <213> hPTHrP (7-141)

<400> 42
 Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg Arg Arg Phe
 1 5 10 15
 Phe Leu His His Leu Ile Ala Glu Ile His Thr Ala Glu Ile Arg Ala
 20 25 30
 Thr Ser Glu Val Ser Pro Asn Ser Lys Pro Ser Pro Asn Thr Lys Asn
 35 40 45
 His Pro Val Arg Phe Gly Ser Asp Asp Glu Gly Arg Tyr Leu Thr Gln
 50 55 60
 Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu Gln Pro Leu Lys Thr Pro
 65 70 75 80
 Gly Lys Lys Lys Lys Gly Lys Pro Gly Lys Arg Lys Glu Gln Glu Lys
 85 90 95
 Lys Lys Arg Arg Thr Arg Ser Ala Trp Leu Asp Ser Gly Val Thr Gly
 100 105 110
 Ser Gly Leu Glu Gly Asp His Leu Ser Asp Thr Ser Thr Thr Ser Leu
 115 120 125
 Glu Leu Asp Ser Arg Arg His
 130 135

<210> 43
 <211> 203
 <212> PRT
 <213> hPTHrP (7-173)

<400> 43
 Gln Gln Trp Ser Val Ala Val Phe Leu Leu Ser Tyr Ala Val Pro Ser
 1 5 10 15
 Cys Gly Arg Ser Val Glu Gly Leu Ser Arg Arg Leu Lys Arg Ala Val
 20 25 30
 Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu

-13-

35					40					45					
Arg	Arg	Arg	Phe	Phe	Leu	His	His	Leu	Ile	Ala	Glu	Ile	His	Thr	Ala
50						55					60				
Glu	Ile	Arg	Ala	Thr	Ser	Glu	Val	Ser	Pro	Asn	Ser	Lys	Pro	Ser	Pro
65					70					75					80
Asn	Thr	Lys	Asn	His	Pro	Val	Arg	Phe	Gly	Ser	Asp	Asp	Glu	Gly	Arg
			85						90					95	
Tyr	Leu	Thr	Gln	Glu	Thr	Asn	Lys	Val	Glu	Thr	Tyr	Lys	Glu	Gln	Pro
			100					105					110		
Leu	Lys	Thr	Pro	Gly	Lys	Lys	Lys	Lys	Gly	Lys	Pro	Gly	Lys	Arg	Lys
			115					120				125			
Glu	Gln	Glu	Lys	Lys	Lys	Arg	Arg	Thr	Arg	Ser	Ala	Trp	Leu	Asp	Ser
	130					135					140				
Gly	Val	Thr	Gly	Ser	Gly	Leu	Glu	Gly	Asp	His	Leu	Ser	Asp	Thr	Ser
145					150					155					160
Thr	Thr	Ser	Leu	Glu	Leu	Asp	Ser	Arg	Thr	Ala	Leu	Leu	Trp	Gly	Leu
				165					170					175	
Lys	Lys	Lys	Lys	Glu	Asn	Asn	Arg	Arg	Thr	His	His	Met	Gln	Leu	Met
				180				185					190		
Ile	Ser	Leu	Phe	Lys	Ser	Pro	Leu	Leu	Leu	Leu					
		195					200								

<210> 44
 <211> 44
 <212> PRT
 <213> hPTH (1-44)

<400> 44
 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
 1 5 10 15
 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
 20 25 30
 Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg
 35 40

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/028420 A3

(51) International Patent Classification?: **A61K 38/29**,
31/7088, 48/00, C12N 5/08, A61K 9/127, 7/06, 7/48,
A61P 17/00, 35/00, A61K 38/17, 38/00, 38/24 // (A61K
38/29, 31:59)

(81) Designated States (*national*): AU, CA, JP, KR, US.

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(21) International Application Number: PCT/US01/31082

(22) International Filing Date: 5 October 2001 (05.10.2001)

Published:

— with international search report

(25) Filing Language: English

(26) Publication Language: English

(88) Date of publication of the international search report:
14 August 2003

(30) Priority Data:
60/238,134 6 October 2000 (06.10.2000) US

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 08/2003 of 20 February 2003, Sec-
tion II

(71) Applicant and

(72) Inventor: **HOLICK, Michael, F.** [US/US]; 31 Bishop
Lane, Sudbury, MA 01776 (US).

(74) Agents: **ESMOND, Robert, W. et al.**; Sterne, Kessler,
Goldstein & Fox P.L.L.C., 1100 New York Avenue, N.W.,
Suite 600, Washington, DC 20005-3934 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 02/028420 A3

(54) Title: REGULATION OF CELL PROLIFERATION AND DIFFERENTIATION USING TOPICALLY APPLIED NUCLEIC ACID MOLECULES

(57) Abstract: Methods are disclosed for the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorder, such as psoriasis, and skin cancer for enhancing wound healing, for stimulating hair growth and inhibiting hair growth, by administration of nucleic acid molecules encoding parathyroid hormone (PTH), parathyroid related peptide (PTHrP), or fragment, analog or derivative thereof, and salts thereof, encapsulated by particular liposomes or incorporated into a porous biocompatible matrix.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/29 A61K31/7088 A61K48/00 C12N5/08 A61K9/127
A61K7/06 A61K7/48 A61P17/00 A61P35/00 A61K38/17
A61K38/00 A61K38/24 //(A61K38/29,31:59)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 914 126 A (LI LINGNA ET AL) 22 June 1999 (1999-06-22)	1-3, 5-7, 10, 11, 29-35, 37, 39 41
Y	column 5, line 4 - line 31 column 1, line 61 - line 62 column 22, line 21 - line 25	
Y	US 6 066 618 A (HOLICK MICHAEL F) 23 May 2000 (2000-05-23) column 3, line 25 - column 4, line 60 -/-	1-11, 18-20, 29-39

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 March 2003

Date of mailing of the international search report

02 04 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bayrak, S

INTERNATIONAL SEARCH REPORT

Inte nal Application No

PC 17/US 01/31082

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HOLICK M F ET AL: "A parathyroid hormone antagonist stimulates epidermal proliferation and hair growth in mice" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 91, no. 17, August 1994 (1994-08), pages 8014-8016, XP002213035 ISSN: 0027-8424 the whole document	1-11, 18-20, 29-39
Y	WO 97 38729 A (UNIV MICHIGAN) 23 October 1997 (1997-10-23) page 16 page 41, line 6 - line 37	1-11, 18-20, 28-39
Y	WYSOLMERSKI JOHN J ET AL: "Overexpression of parathyroid hormone-related protein in the skin of transgenic mice interferes with hair follicle development." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 91, no. 3, 1994, pages 1133-1137, XP002218988 1994 ISSN: 0027-8424 the whole document	1-11, 18-20, 29-39
X	US 5 744 128 A (HOLICK MICHAEL F) 28 April 1998 (1998-04-28)	12-17, 21-23, 26,40
Y	column 4, line 54 - line 56 column 5, line 15 -column 9 column 9, line 60 -column 10, line 2	28,41
A	SHARPE G R ET AL: "Human keratinocytes express transcripts for three isoforms of parathyroid hormone-related protein (PTHrP), but not for the parathyroid hormone/PTHrP receptor: Effects of 1,25(OH) ₂ vitamin D ₃ ." BRITISH JOURNAL OF DERMATOLOGY, vol. 138, no. 6, June 1998 (1998-06), pages 944-951, XP002234398 ISSN: 0007-0963 the whole document	1-41

INTERNATIONAL SEARCH REPORT

ational application No.
PCT/US 01/31082

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-11, 18-20,36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: claims 1-41 (all partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 01 31082

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11,18-20,36-38

Claims 1-11,18-20, 36-38: inhibition of proliferation/enhancing differentiation of a mammalian skin or hair cell by the administration of a proliferation inhibiting/differentiation enhancing nucleic acid molecule, such as defined in claim 1.

2. Claims: 29-35,39

Claims 29-35,39: induction of proliferation of a mammalian skin or hair cell by the administration of a proliferation inducing nucleic acid molecule, such as defined in claims 29.

3. Claims: 12-17,21-28,40,41

Claims 12-17,21-28,40,41: inhibition of proliferation/enhancing differentiation of a mammalian skin or hair cell by the administration of a proliferation inhibiting/differentiation enhancing nucleic acid molecule, such as defined in claim 1, and an active vitamin D compound.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: claims 1-41 (all partially)

1. Claims 1-4,7-10,12-34,37-41 relate to compounds defined by reference to a desirable characteristic or property, namely "...a nucleic acid molecule, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or in vivo in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth" or "...a nucleic acid molecule, wherein the peptide encoded by the nucleic acid molecule is at least 3 amino acids long, has at least 10% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP, and is capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro of cultured human keratinocytes by ...inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes, or in vivo in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth". The claims 1-4,7-10,12-34,37-41 cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity because the above expressions are unclear and leave the reader in doubt as to the meaning of the technical feature to which they refer, thereby rendering the definition of the subject-matter of said claims unclear (Article 6 PCT). Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

2. Claims 1-8,11-32,35-41 relate to the use of a pharmaceutical preparation for the treatment of "hyperproliferative skin disorder", "inhibition of proliferation/enhancing differentiation of a mammalian skin or hair cell", or "inducing proliferation of a mammalian skin or hair cell" which is a generic term for a multitude of different diseases. The claim thus covers a multitude of diseases, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such diseases. Consequently, the claims lack support and the application lacks disclosure. Independent of the above reasoning, claims 1,8,37 also lack clarity because it is not fully possible to determine the diseases for which protection might legitimately be sought (Article 6 PCT).

Consequently, the search for the first subject has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely nucleic acid molecules as disclosed in claims 5, 6, and 35 in relation to the treatment of diseases as defined in claims 9,10,33,34; and with due regard to the general concept of the invention.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 01 /31082

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT, US 01/31082

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5914126	A	22-06-1999	US 5753263 A	19-05-1998
			US 5641508 A	24-06-1997
			US 6224901 B1	01-05-2001
			US 5965157 A	12-10-1999
			AT 209887 T	15-12-2001
			AU 6554594 A	24-10-1994
			CA 2159626 A1	13-10-1994
			DE 69429337 D1	17-01-2002
			DE 69429337 T2	10-10-2002
			EP 0692972 A1	24-01-1996
			JP 2950520 B2	20-09-1999
			JP 8511510 T	03-12-1996
			US 6261596 B1	17-07-2001
			WO 9422468 A1	13-10-1994
US 6066618	A	23-05-2000	US 5840690 A	24-11-1998
			US 5527772 A	18-06-1996
			WO 9204039 A1	19-03-1992
			AT 138685 T	15-06-1996
			AU 2788089 A	23-05-1989
			CA 1326460 A1	25-01-1994
			DE 3855331 D1	04-07-1996
			DE 3855331 T2	24-10-1996
			EP 0415924 A1	13-03-1991
			JP 2802084 B2	21-09-1998
			JP 3505517 T	05-12-1991
			WO 8903873 A1	05-05-1989
WO 9738729	A	23-10-1997	US 5962427 A	05-10-1999
			AU 710386 B2	16-09-1999
			AU 2821297 A	07-11-1997
			CA 2251655 A1	23-10-1997
			CN 1226835 A	25-08-1999
			EP 0892644 A1	27-01-1999
			JP 2001519767 T	23-10-2001
			KR 2000005376 A	25-01-2000
			NO 984729 A	14-12-1998
			PL 343864 A1	10-09-2001
			RU 2170104 C2	10-07-2001
			WO 9738729 A1	23-10-1997
US 5744128	A	28-04-1998	AU 5548396 A	21-11-1996
			US 5958384 A	28-09-1999
			WO 9634596 A2	07-11-1996

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.